Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acidosis, Respiratory
Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2.
Acne Vulgaris
Neuropeptides and sebaceous glands.
Acne Vulgaris
New aspects in acne inflammation.
Acne Vulgaris
Sebaceous glands in acne patients express high levels of neutral endopeptidase.
Acquired Immunodeficiency Syndrome
Treatment of refractory diarrhoea in AIDS with acetorphan and octreotide: a randomized crossover study.
Acute Coronary Syndrome
Omapatrilat limits infarct size and lowers the threshold for induction of myocardial preconditioning through a bradykinin receptor-mediated mechanism.
Acute Kidney Injury
Down regulation of kidney neutral endopeptidase mRNA, protein and activity during acute renal failure: possible mechanism for ischemia-induced acute renal failure in rats?
Acute Kidney Injury
Natriuretic and renoprotective effect of chronic oral neutral endopeptidase inhibition in acute renal failure.
Acute Kidney Injury
Protection of kidney function and tissue integrity by pharmacologic use of natriuretic peptides and neprilysin inhibitors.
Acute Kidney Injury
Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage.
Acute Kidney Injury
Urinary neprilysin for early detection of acute kidney injury after cardiac surgery: A prospective observational study.
Acute Lung Injury
Expression of neutral endopeptidase activity during clinical and experimental acute lung injury.
Adenocarcinoma
Characterization of the promoter region of the rat neprilysin gene.
Adenocarcinoma
Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues.
Adenomyosis
Expression of aminopeptidase N and neutral endopeptidase on the endometrial stromal cells in endometriosis and adenomyosis.
Airway Obstruction
Effects of inhaled or intravenous thiorphan on substance P-induced airway obstruction.
Alagille Syndrome
Lack of hepatocellular CD10 along bile canaliculi is physiologic in early childhood and persistent in Alagille syndrome.
Albuminuria
Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial.
Albuminuria
Urinary Proteome Analysis Identified Neprilysin and VCAM as Proteins Involved in Diabetic Nephropathy.
Alzheimer Disease
(-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression.
Alzheimer Disease
5-HIAA induces neprilysin to ameliorate pathophysiology and symptoms in a mouse model for Alzheimer's disease.
Alzheimer Disease
A highly sensitive peptide substrate for detecting two Abeta-degrading enzymes: neprilysin and insulin-degrading enzyme.
Alzheimer Disease
A monoclonal antibody to common acute lymphoblastic leukemia antigen (neutral endopeptidase) immunostains senile plaques in the brains of patients with Alzheimer's disease.
Alzheimer Disease
A novel system for in vivo neprilysin gene delivery using a syringe electrode.
Alzheimer Disease
Accumulation of Insoluble Amyloid-? in Down's Syndrome is Associated with Increased BACE-1 and Neprilysin Activities.
Alzheimer Disease
Accumulation of murine amyloid-? mimics early Alzheimer's disease.
Alzheimer Disease
Activating AhR alleviates cognitive deficits of Alzheimer's disease model mice by upregulating endogenous A? catabolic enzyme Neprilysin.
Alzheimer Disease
Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels.
Alzheimer Disease
Anti-amyloid activity of neprilysin in plaque-bearing mouse models of Alzheimer's disease.
Alzheimer Disease
Association between neprilysin polymorphisms and sporadic Alzheimer's disease.
Alzheimer Disease
Association of the Neprilysin gene with susceptibility to late-onset Alzheimer's disease.
Alzheimer Disease
Associations of Neprilysin Activity in CSF with Biomarkers for Alzheimer's Disease.
Alzheimer Disease
Brain neprilysin activity and susceptibility to transgene-induced Alzheimer amyloidosis.
Alzheimer Disease
Cell Surface Expression of the Major Amyloid-? Peptide (A?)-degrading Enzyme, Neprilysin, Depends on Phosphorylation by Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase (MEK) and Dephosphorylation by Protein Phosphatase 1a.
Alzheimer Disease
Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease.
Alzheimer Disease
Co-Administration of TiO2 Nanowired Mesenchymal Stem Cells with Cerebrolysin Potentiates Neprilysin Level and Reduces Brain Pathology in Alzheimer's Disease.
Alzheimer Disease
Combined risk effects of IDE and NEP gene variants on Alzheimer disease.
Alzheimer Disease
Complementary distributions of amyloid-beta and neprilysin in the brains of dogs and cats.
Alzheimer Disease
Computer modeling and nanosecond simulation of the enzyme-substrate complex of the common lymphoblastic leukemia antigen (neprilysin) indicates shared residues at the primary specificity pocket (S1') with matrix metalloproteases.
Alzheimer Disease
Convection-Enhanced Delivery of Neprilysin: A Novel Amyloid-?-Degrading Therapeutic Strategy.
Alzheimer Disease
Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy.
Alzheimer Disease
Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy.
Alzheimer Disease
Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging.
Alzheimer Disease
Design of Peptide Substrate for Sensitively and Specifically Detecting Two A?-Degrading Enzymes: Neprilysin and Angiotensin-Converting Enzyme.
Alzheimer Disease
Developmental Profile of Brain Neprilysin Expression Correlates with Olfactory Behaviour of Rats.
Alzheimer Disease
Dinucleotide repeat polymorphisms in the neprilysin gene are not associated with sporadic Alzheimer's disease.
Alzheimer Disease
Distinct subcellular patterns of neprilysin protein and activity in the brains of Alzheimer's disease patients, transgenic mice and cultured human neuronal cells.
Alzheimer Disease
DNA methylation level of the neprilysin promoter in Alzheimer's disease brains.
Alzheimer Disease
Drosophila Neprilysins Are Involved in Middle-Term and Long-Term Memory.
Alzheimer Disease
Dynamic alteration of neprilysin and endothelin-converting enzyme in age-dependent APPswe/PS1dE9 mouse model of Alzheimer's disease.
Alzheimer Disease
Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Directions.
Alzheimer Disease
Effects of HNE-modification induced by Abeta on neprilysin expression and activity in SH-SY5Y cells.
Alzheimer Disease
ENDOCANNABINOIDS RECEPTORS MEDIATED CENTRAL AND PERIPHERAL EFFECTS (REVIEW).
Alzheimer Disease
Engineering neprilysin activity and specificity to create a novel therapeutic for Alzheimer's disease.
Alzheimer Disease
Estrogen Regulation of the Neprilysin Gene Through A Hormone-Responsive Element.
Alzheimer Disease
Etiology of sporadic Alzheimer's disease: somatostatin, neprilysin, and amyloid beta peptide.
Alzheimer Disease
Evaluation of neprilysin sequence variation in relation to CSF ?-Amyloid levels and Alzheimer disease risk.
Alzheimer Disease
Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease.
Alzheimer Disease
Expression of Somatostatin, Cortistatin, and Their Receptors, as well as Dopamine Receptors, but not of Neprilysin, are Reduced in the Temporal Lobe of Alzheimer's Disease Patients.
Alzheimer Disease
Extracellular Vesicles as a Neprilysin Delivery System Memory Improvement in Alzheimer's Disease.
Alzheimer Disease
Genetic variation in MME in relation to neprilysin protein and enzyme activity, A? levels, and Alzheimer's disease risk.
Alzheimer Disease
Genetically engineered exosomes display RVG peptide and selectively enrich a neprilysin variant: a potential formulation for the treatment of Alzheimer's disease.
Alzheimer Disease
Histone Acetylation Regulates Natriuretic Peptides and Neprilysin Gene Expressions in Diabetic Cardiomyopathy and Nephropathy.
Alzheimer Disease
Identification of the sites of 4-hydroxy-2-nonenal and neprilysin adduction using a linear trap quadrapole Velos Pro-Orbitrap Elite mass spectrometer.
Alzheimer Disease
Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid.
Alzheimer Disease
Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications.
Alzheimer Disease
Inhibition of neprilysin by infusion of thiorphan into the hippocampus causes an accumulation of amyloid Beta and impairment of learning and memory.
Alzheimer Disease
Lack of association of neprilysin gene polymorphisms with Alzheimer's disease in a southern Chinese community.
Alzheimer Disease
Lack of association of neprilysin polymorphism with Alzheimer's disease and Alzheimer's disease-type neuropathological changes.
Alzheimer Disease
Limitations of Sacubitril/Valsartan in the Management of Heart Failure.
Alzheimer Disease
Locomotor and geotactic behavior of Drosophila melanogaster over-expressing neprilysin 2.
Alzheimer Disease
Long-term neprilysin inhibition - implications for ARNIs.
Alzheimer Disease
Loss of neprilysin alters protein expression in the brain of Alzheimer's disease model mice.
Alzheimer Disease
Mercury reduces the enzymatic activity of neprilysin in differentiated SH-SY5Y cells.
Alzheimer Disease
Meta-analysis of expression and function of neprilysin in Alzheimer's disease.
Alzheimer Disease
Meta-analysis of the association between two neprilysin gene polymorphisms and Alzheimer's disease.
Alzheimer Disease
miR-26b inhibits total neurite outgrowth, promotes cells apoptosis and downregulates neprilysin in Alzheimer's disease.
Alzheimer Disease
Mitochondria-targeted catalase reduces abnormal APP processing, amyloid ? production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension.
Alzheimer Disease
Mutation screening and association study of the neprilysin gene in sporadic Alzheimer's disease in Chinese persons.
Alzheimer Disease
Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer's disease.
Alzheimer Disease
Neprilysin activity and expression are controlled by nicastrin.
Alzheimer Disease
Neprilysin and A? Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer's Disease.
Alzheimer Disease
Neprilysin and amyloid beta peptide degradation.
Alzheimer Disease
Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity.
Alzheimer Disease
Neprilysin Confers Genetic Susceptibility to Alzheimer's Disease in Han Chinese.
Alzheimer Disease
Neprilysin Deficiency Alters the Neuropathological and Behavioral Phenotype in the 5XFAD Mouse Model of Alzheimer's Disease.
Alzheimer Disease
Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease.
Alzheimer Disease
Neprilysin gene transfer reduces human amyloid pathology in transgenic mice.
Alzheimer Disease
Neprilysin gene transfer: A promising therapeutic approach for Alzheimer's disease.
Alzheimer Disease
Neprilysin impedes islet amyloid formation by inhibition of fibril formation rather than peptide degradation.
Alzheimer Disease
Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen.
Alzheimer Disease
Neprilysin is poorly expressed in the prefrontal cortex of aged dogs with cognitive dysfunction syndrome.
Alzheimer Disease
Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split?
Alzheimer Disease
Neprilysin-Like Activity Correlates with CSF-Tau and Phospho-Tau in Patients with Alzheimer's Disease.
Alzheimer Disease
Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function.
Alzheimer Disease
Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease.
Alzheimer Disease
Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease.
Alzheimer Disease
Nitric Oxide Decreases the Enzymatic Activity of Insulin Degrading Enzyme in APP/PS1 Mice.
Alzheimer Disease
No association between polymorphisms in the neprilysin promoter region and Swedish Alzheimer's disease patients.
Alzheimer Disease
Oxidized neprilysin in aging and Alzheimer's disease brains.
Alzheimer Disease
Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease.
Alzheimer Disease
Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia.
Alzheimer Disease
Pharmacological Heart Failure Therapy in Children: Focus on Inotropic Support.
Alzheimer Disease
Polyhydroxycurcuminoids but not curcumin upregulate neprilysin and can be applied to the prevention of Alzheimer's disease.
Alzheimer Disease
Polymorphisms in neprilysin gene affect the risk of Alzheimer's disease in Finnish patients.
Alzheimer Disease
Possible increased risk for Alzheimer's disease associated with neprilysin gene.
Alzheimer Disease
Possible role of resveratrol targeting estradiol and neprilysin pathways in lipopolysaccharide model of Alzheimer disease.
Alzheimer Disease
Possible role of tau in mediating pathological effects of apoE4 in vivo prior to and following activation of the amyloid cascade.
Alzheimer Disease
Proteinase dysbalance in pathology: the neprilysin (NEP) and angiotensin-converting enzyme (ACE) families.
Alzheimer Disease
Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer's disease mice.
Alzheimer Disease
Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide.
Alzheimer Disease
Regulation of Neprilysin Activity and Cognitive Functions in Rats After Prenatal Hypoxia.
Alzheimer Disease
Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain.
Alzheimer Disease
Retrograde transport of masseter muscle-derived neprilysin to hippocampus.
Alzheimer Disease
Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation.
Alzheimer Disease
Structures of soluble rabbit neprilysin complexed with phosphoramidon or thiorphan.
Alzheimer Disease
The antioxidant xanthorrhizol prevents amyloid-?-induced oxidative modification and inactivation of neprilysin.
Alzheimer Disease
The Association between Neprilysin gene polymorphisms and Alzheimer's disease in Tibetan population.
Alzheimer Disease
The characteristics of astrocyte on A? clearance altered in Alzheimer's disease were reversed by anti-inflammatory agent (+)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeate.
Alzheimer Disease
The extracellular matrix enriched with membrane metalloendopeptidase and insulin-degrading enzyme suppresses the deposition of amyloid-beta peptide in Alzheimer's disease cell models.
Alzheimer Disease
Up-regulation of neprilysin mediates the protection of fructo-oligosaccharides against Alzheimer's disease.
Alzheimer Disease
Valproic acid reduces neuritic plaque formation and improves learning deficits in APP(Swe) /PS1(A246E) transgenic mice via preventing the prenatal hypoxia-induced down-regulation of neprilysin.
Alzheimer Disease
Wide-Ranging Effects on the Brain Proteome in a Transgenic Mouse Model of Alzheimer's Disease Following Treatment with a Brain-Targeting Somatostatin Peptide.
Alzheimer Disease
[Association of the neprilysin and apolipoprotein E gene polymorphisms with Alzheimer's disease in Xinjiang Uygur population.]
Alzheimer Disease
[Effect of Electroacupuncture on Levels of ?-amyloid and Neprilysin Proteins in the Cerebral Cortex of Alzheimer's Disease Mice Based on "Mutual Assistance of Kidney and Brain" Theory].
Alzheimer Disease
[Effects of Naoerkang on expressions of beta-amyloid peptide 1-42 and neprilysin in hippocampus in a rat model of Alzheimer's disease]
Amyloidosis
Brain neprilysin activity and susceptibility to transgene-induced Alzheimer amyloidosis.
Amyloidosis
Cell Surface Expression of the Major Amyloid-? Peptide (A?)-degrading Enzyme, Neprilysin, Depends on Phosphorylation by Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase (MEK) and Dephosphorylation by Protein Phosphatase 1a.
Amyloidosis
Neprilysin deficiency-dependent impairment of cognitive functions in a mouse model of amyloidosis.
Amyloidosis
Neprilysin gene transfer reduces human amyloid pathology in transgenic mice.
Amyloidosis
Overexpression of neprilysin reduces alzheimer amyloid-beta42 (Abeta42)-induced neuron loss and intraneuronal Abeta42 deposits but causes a reduction in cAMP-responsive element-binding protein-mediated transcription, age-dependent axon pathology, and premature death in Drosophila.
Amyloidosis
Update in recent clinical trials in heart failure.
Anaphylaxis
Phosphoramidon augments contraction of guinea pig tracheal smooth muscle induced by histamine and leukotriene-D4.
Anaphylaxis
Role of neurogenic inflammation in antigen-induced vascular extravasation in guinea pig trachea.
Anemia
Update in recent clinical trials in heart failure.
Anemia, Hypochromic
First Report of Capsicum chlorosis virus Causing Yellow Stripes on Calla Lilies in Taiwan
Anemia, Hypochromic
First Report of Capsicum chlorosis virus Causing Yellow Stripes on Calla Lilies in Taiwan.
Anemia, Hypochromic
First Report of Capsicum chlorosis virus Infecting Amaryllis and Blood Lily in Taiwan
Anemia, Hypochromic
First Report of Capsicum chlorosis virus Infecting Amaryllis and Blood Lily in Taiwan.
Anemia, Hypochromic
First Report of Capsicum chlorosis virus Infecting Chromolaena odorata L. in Yunnan, China.
Anemia, Hypochromic
Identification of Common Epitopes on a Conserved Region of NSs Proteins Among Tospoviruses of Watermelon silver mottle virus Serogroup
Anemia, Hypochromic
Identification of Common Epitopes on a Conserved Region of NSs Proteins Among Tospoviruses of Watermelon silver mottle virus Serogroup.
Anemia, Hypochromic
Mosaic Disease of Calla Lily Caused by a New Potyvirus in Taiwan.
Anemia, Hypochromic
Mosaic disease of calla lily caused by a new potyvirus in Taiwan.
Anemia, Hypochromic
Serological relationship between Melon yellow spot virus and Watermelon silver mottle virus and differential detection of the two viruses in cucurbits.
Anemia, Iron-Deficiency
Update in recent clinical trials in heart failure.
Aneurysm, Dissecting
Simplified technique for hemi-arch replacement during open distal anastomosis: the "calla" method.
Angioedema
Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.
Angioedema
Angioedema induced by cardiovascular drugs: new players join old friends.
Angioedema
Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results.
Angioedema
Angioedema with renin angiotensin system drugs and neutral endopeptidase inhibitors.
Angioedema
Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date.
Angioedema
Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy.
Angioedema
Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact.
Angioedema
Cardiovascular and Diabetic Medications That Cause Bradykinin-Mediated Angioedema.
Angioedema
Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
Angioedema
Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-Like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation In The Rat.
Angioedema
Critical angioedema induced by a renin angiotensin system blocker in the contemporary era of increasing heart failure: A case report and commentary.
Angioedema
Discovery of TD-0212, an Orally Active Dual Pharmacology AT1 Antagonist and Neprilysin Inhibitor (ARNI).
Angioedema
Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
Angioedema
Neprilysin Inhibitors and Bradykinin.
Angioedema
Novel therapeutic targets for hypertension.
Angioedema
Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.
Angioedema
[Neprilysin inhibition and chronic kidney disease].
Aortic Aneurysm, Abdominal
Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs.
Aortic Aneurysm, Abdominal
Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II-Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension.
Aortic Valve Insufficiency
Interaction Between Sacubitril and Valsartan in Preventing Heart Failure Induced by Aortic Valve Insufficiency in Rats.
Aortic Valve Stenosis
Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure.
Arrhythmias, Cardiac
Angiotensin receptor-neprilysin inhibitior (thiorphan/irbesartan) decreased ischemia-reperfusion induced ventricular arrhythmias in rat; in vivo study.
Arthritis
D-phenylalanine and other enkephalinase inhibitors as pharmacological agents: implications for some important therapeutic application.
Arthritis
Elevated synovial tissue concentration of the common acute lymphoblastic leukaemia antigen (CALLA)-associated neutral endopeptidase (3.4.24.11) in human chronic arthritis.
Arthritis
Enkephalinase: a physiologic neuroimmunomodulator detected in the synovial fluid.
Arthritis
Neprilysin levels in plasma and synovial fluid of juvenile idiopathic arthritis patients.
Arthritis
Structures of soluble rabbit neprilysin complexed with phosphoramidon or thiorphan.
Arthritis
The analgesic effects of morphine, but not those of the enkephalinase inhibitor thiorphan, are enhanced in arthritic rats.
Arthritis, Juvenile
Neprilysin levels in plasma and synovial fluid of juvenile idiopathic arthritis patients.
Arthritis, Rheumatoid
Enkephalinase: a physiologic neuroimmunomodulator detected in the synovial fluid.
Arthritis, Rheumatoid
Interaction analysis between BLK rs13277113 polymorphism and BANK1 rs3733197 polymorphism, MMEL1/TNFRSF14 rs3890745 polymorphism in determining susceptibility to rheumatoid arthritis.
Arthritis, Rheumatoid
Neutral endopeptidase (3.4.24.11) in plasma and synovial fluid of patients with rheumatoid arthritis. A marker of disease activity or a regulator of pain and inflammation?
Asthma
Airway neuropeptides and neutral endopeptidase in asthma.
Asthma
Decreased serum neutral endopeptidase activity in children with bronchial asthma.
Asthma
Effect of an inhaled neutral endopeptidase inhibitor, phosphoramidon, on baseline airway calibre and bronchial responsiveness to bradykinin in asthma.
Asthma
Effect of inhaled atrial natriuretic peptide and a neutral endopeptidase inhibitor on histamine-induced bronchoconstriction.
Asthma
Enhanced expression of neutral endopeptidase (NEP) in airway epithelium in biopsies from steroid- versus nonsteroid-treated patients with atopic asthma.
Asthma
Epithelial modulation of cholinergic responses in rabbit trachea is partly due to neutral endopeptidase activity.
Asthma
European drug market entries 2015 with new mechanisms of action.
Asthma
Neutral endopeptidase inhibition with inhaled phosphoramidon: no effect on bronchial responsiveness to adenosine 5'-monophosphate (AMP) in asthma.
Asthma
No effect of the oral neutral endopeptidase inhibitor candoxatril, on bronchomotor tone and histamine reactivity in asthma.
Asthma
Regulation of airway neurogenic inflammation by neutral endopeptidase.
Asthma
Role of neutral endopeptidase and angiotensin converting enzyme in asthma.
Asthma
[Enkephalinase activity in the guinea pig model of asthma]
Asthma
[Membrane metalloendopeptidase (CD10/CALLA): distribution, physiologic and pathophysiologic functions and its inhibitors]
Astrocytoma
Hydrolysis of atrial and brain natriuretic peptides by the human astrocytoma clone D384 and the neuroblastoma line SH-SY5Y.
Atherosclerosis
Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis.
Atherosclerosis
Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice.
Atherosclerosis
Omapatrilat, an angiotensin-converting enzyme and neutral endopeptidase inhibitor, attenuates early atherosclerosis in diabetic and in nondiabetic low-density lipoprotein receptor-deficient mice.
Atherosclerosis
Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II-Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension.
Atherosclerosis
Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition.
Atherosclerosis
Vascular neutral endopeptidase inhibition improves endothelial function and reduces intimal hyperplasia.
Atherosclerosis
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
Atrial Fibrillation
Atrial fibrillation down-regulates renal neutral endopeptidase expression and induces profibrotic pathways in the kidney.
Atrial Fibrillation
Key advances in clinical cardiology.
Atrial Fibrillation
National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018.
Bacterial Infections
[Biological properties of agents of bacterial infection in Hyacinthus orientalis Z. and Calla Z]
Blast Crisis
A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
Blast Crisis
Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors.
Blast Crisis
Comparison of the expression of terminal deoxynucleotidyl transferase and common acute lymphoblastic leukemia antigen in selected hematologic malignancies.
Blast Crisis
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.
Blast Crisis
Human leukemia-associated antigen: relation to a family of surface glycoproteins.
Blast Crisis
Leukemia-associated antigens in ALL.
Blast Crisis
Separation of lymphoid and myeloid blasts in the mixed blast crisis of chronic myelogenous leukemia: no evidence for Ig gene rearrangement in CALLA-positive blasts.
Bone Resorption
Inhibition of bone resorption in vitro by human enkephalinase (EC 3.4.24.11), a neutral metalloendopeptidase.
Borna Disease
Degradation of amyloid ? peptide by neprilysin expressed from Borna disease virus vector.
Bradycardia
Cardiovascular effects of nociceptin in unanesthetized mice.
Bradycardia
Restorative effect of atrial natriuretic peptide or chronic neutral endopeptidase inhibition on blunted cardiopulmonary vagal reflexes in aged rats.
Brain Diseases
Messenger RNA-based therapeutics for brain diseases: An animal study for augmenting clearance of beta-amyloid by intracerebral administration of neprilysin mRNA loaded in polyplex nanomicelles.
Brain Injuries, Traumatic
A Neprilysin Polymorphism and Amyloid-beta Plaques Following Traumatic Brain Injury.
Breast Cyst
Angiotensin-converting enzyme and enkephalinase in human breast cyst fluid.
Breast Cyst
Neutral endopeptidase activity in breast cysts.
Breast Neoplasms
Defining central themes in breast cancer biology by differential proteomics: conserved regulation of cell spreading and focal adhesion kinase.
Breast Neoplasms
Endostatin and irradiation modifies the activity of ADAM10 and neprilysin in breast cancer cells.
Breast Neoplasms
Epigenetic suppression of neprilysin regulates breast cancer invasion.
Breast Neoplasms
On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer.
Breast Neoplasms
Thalidomide combined with irradiation alters the activity of two proteases.
Bronchial Hyperreactivity
Correlation between neutral endopetidase (NEP) 3.4.24.11 in serum and the degree of the bronchial hyperreactivity.
Bronchial Hyperreactivity
Effect of active sensitization on the bronchopulmonary responses to tachykinins in the guinea pig. Modulation by peptidase inhibitors.
Bronchial Hyperreactivity
Role of tachykinins and neutral endopeptidase in toluene diisocyanate-induced bronchial hyperresponsiveness in guinea pigs.
Bronchial Spasm
Augmentation of neurally evoked cholinergic bronchoconstrictor responses by prejunctional NK2 receptors in the guinea-pig.
Bronchitis, Chronic
Pre-protachykinin-A mRNA is increased in the airway epithelium of smokers with chronic bronchitis.
Burkitt Lymphoma
Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationships between antigen expression and type of chromosomal translocation.
Burkitt Lymphoma
Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement.
Burkitt Lymphoma
Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
Burkitt Lymphoma
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.
Burkitt Lymphoma
Induction of differentiation of African Burkitt's lymphoma cells by phorbol ester: possible relation with early B cells.
Carcinogenesis
Membrane metalloendopeptidase suppresses prostate carcinogenesis by attenuating effects of gastrin-releasing peptide on stem/progenitor cells.
Carcinogenesis
Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia.
Carcinogenesis
Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis.
Carcinoma
Anti-progressive effect of neutral endopeptidase 24.11 (NEP/CD10) on cervical carcinoma in vitro and in vivo.
Carcinoma
CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung.
Carcinoma
CD10/neutral endopeptidase 24.11 regulates fetal lung growth and maturation in utero by potentiating endogenous bombesin-like peptides.
Carcinoma
Characterization of the promoter region of the rat neprilysin gene.
Carcinoma
Cigarette smoke condensate could promote human bronchial epithelial BEAS-2B cell migration through shifting neprilysin trafficking.
Carcinoma
Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma.
Carcinoma
Distinct patterns of endothelin axis expression in primary prostate cancer.
Carcinoma
Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients.
Carcinoma
Expression and Regulatory Network Analysis of MiR-139-3p, a New Potential Serum Biomarker for Esophageal Squamous Cell Carcinoma Based on Bioinformatics Analysis.
Carcinoma
Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues.
Carcinoma
Membrane Metalloendopeptidase (MME) Suppresses Metastasis of Esophageal Squamous Cell Carcinoma (ESCC) by Inhibiting FAK-RhoA Signaling Axis.
Carcinoma
Neuropeptide Levels as well as Neprilysin Activity Decrease in Renal Cell Carcinoma.
Carcinoma
Neutral endopeptidase 24.11/CD10 suppresses progressive potential in ovarian carcinoma in vitro and in vivo.
Carcinoma
Renal Cell Carcinoma Presenting as Pleural Effusion.
Carcinoma
Utility of CD10 and RCCma in the diagnosis of metastatic conventional renal-cell adenocarcinoma by fine-needle aspiration biopsy.
Carcinoma, Hepatocellular
Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas.
Carcinoma, Hepatocellular
Detection of neutral endopeptidase 24.11 (neprilysin) in human hepatocellular carcinomas by immunocytochemistry.
Carcinoma, Hepatocellular
Ectopeptidases are differentially expressed in hepatocellular carcinomas.
Carcinoma, Hepatocellular
Elevated hepatocyte paraffin 1 and neprilysin expression in hepatocellular carcinoma are correlated with longer survival.
Carcinoma, Hepatocellular
High concentration of neutral endopeptidase (enkephalinase E.C. 3.4.24.11) in a malignant tumor: rat hepatoma 3924A.
Carcinoma, Hepatocellular
Increased expression of neprilysin (neutral endopeptidase 24.11) in rat and human hepatocellular carcinomas.
Carcinoma, Hepatocellular
Methylation of neutral endopeptidase 24.11 promoter in rat hepatocellular carcinoma.
Carcinoma, Non-Small-Cell Lung
Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung cancer.
Carcinoma, Renal Cell
Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients.
Carcinoma, Renal Cell
Neuropeptide Levels as well as Neprilysin Activity Decrease in Renal Cell Carcinoma.
Carcinoma, Renal Cell
Renal Cell Carcinoma Presenting as Pleural Effusion.
Carcinoma, Small Cell
CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung.
Cardiomegaly
B-type natriuretic Peptide and the right heart.
Cardiomegaly
Effect of chronic neutral endopeptidase inhibition on cardiac hypertrophy after experimental myocardial infarction.
Cardiomegaly
Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
Cardiomegaly
Effect on prolonged inhibition of neutral endopeptidase on cardiac hypertrophy in rats with myocardial infarction.
Cardiomegaly
Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
Cardiomegaly
Effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, CGS 30440, on blood pressure and cardiac hypertrophy in spontaneously hypertensive rats.
Cardiomegaly
Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Cardiomegaly
LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.
Cardiomegaly
Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure.
Cardiomegaly
Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
Cardiomegaly
Sacubitril/Valsartan Improves Left Ventricular Function in Chronic Pressure Overload Independent of Intact Cyclic Guanosine Monophosphate-dependent Protein Kinase I Alpha Signaling.
Cardiomyopathies
Cardioprotective effects of phosphoramidon on myocardial structure and function in murine Chagas' disease.
Cardiomyopathies
Effects of Angiotensin Receptor Neprilysin Inhibitors on Inducibility of Ventricular Arrhythmias in Rats with Ischemic Cardiomyopathy.
Cardiomyopathy, Hypertrophic
Angiotensin receptor neprilysin inhibitor treatment is safe and potentially efficacious in end?stage hypertrophic cardiomyopathy.
Cardiovascular Diseases
Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias.
Cardiovascular Diseases
Bioinformatic analysis of the neprilysin (M13) family of peptidases reveals complex evolutionary and functional relationships.
Cardiovascular Diseases
Cardiovascular effects of natriuretic peptides and their interrelation with endothelin-1.
Cardiovascular Diseases
Clinical potential of endopeptidase-24.11 inhibitors in cardiovascular disease.
Cardiovascular Diseases
Combined Neprilysin and RAS Inhibition in Cardiovascular Diseases: A Review of Clinical Studies.
Cardiovascular Diseases
Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
Cardiovascular Diseases
Dual-Acting Angiotensin Receptor-Neprilysin Inhibition.
Cardiovascular Diseases
Effect of neutral endopeptidase inhibition on the actions of adrenomedullin and endothelin-1 in resistance arteries from patients with chronic heart failure.
Cardiovascular Diseases
Neprilysin Inhibitors in Cardiovascular Disease.
Cardiovascular Diseases
Neutral endopeptidase and angiotensin-converting enzyme inhibitors increase nitric oxide production in isolated canine coronary microvessels by a kinin-dependent mechanism.
Cardiovascular Diseases
Neutral endopeptidase inhibition: the potential of a new therapeutic approach in cardiovascular disease evolves.
Cardiovascular Diseases
New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
Cardiovascular Diseases
Omapatrilat. Bristol-Myers Squibb.
Cardiovascular Diseases
Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects.
Cardiovascular Diseases
Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan.
Cardiovascular Diseases
Radiosynthesis of the 11 C-methyl derivative of LBQ657 for PET investigation of the neprilysin inhibitor sacubitril.
Cardiovascular Diseases
Receptor-based 3D-QSAR study for recognizing true binding mode of mercaptoacyldipeptides at the active site of neutral endopeptidase.
Cardiovascular Diseases
Renal and antihypertensive effects of neutral endopeptidase inhibition in transgenic rats with an extra renin gene.
Cardiovascular Diseases
Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease.
Cardiovascular Diseases
Soluble neprilysin: A versatile biomarker for heart failure, cardiovascular diseases and diabetic complications-A systematic review.
Cardiovascular Diseases
Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
Cardiovascular Diseases
The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients.
Cardiovascular Diseases
The Role of Neprilysin Inhibitors in Cardiovascular Disease.
Cardiovascular Diseases
Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II-Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension.
Cardiovascular Diseases
[Protective role of neutral endopeptidase in cardiovascular diseases]
Catalepsy
Effects of SCH 32615, an enkephalinase inhibitor, on D-1 and D-2 dopamine receptor-mediated behaviors.
Cerebral Amyloid Angiopathy
Association of neprilysin polymorphism with cerebral amyloid angiopathy.
Cerebral Amyloid Angiopathy
Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy.
Cerebral Amyloid Angiopathy
Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy.
Cerebral Amyloid Angiopathy
Long-term neprilysin inhibition - implications for ARNIs.
Cerebral Amyloid Angiopathy
Loss of Neprilysin Function Promotes Amyloid Plaque Formation and Causes Cerebral Amyloid Angiopathy.
Cerebral Amyloid Angiopathy
Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy.
Cerebral Amyloid Angiopathy
Neprilysin Protects against Cerebral Amyloid Angiopathy and A?-Induced Degeneration of Cerebrovascular Smooth Muscle Cells.
Chagas Disease
Amino-terminal fragment of C-type natriuretic peptide precursor and C-type natriuretic peptide do not correlate in patients with Chagas disease: role for neutral endopeptidase.
Chagas Disease
Cardioprotective effects of phosphoramidon on myocardial structure and function in murine Chagas' disease.
Chagas Disease
NT-proCNP And CNP Do Not Correlate In Patients With Chagas' Disease: Role For Neutral Endopeptidase.
Chagas Disease
Tissue Inhibitor of Metalloproteinase-1 Is Increased in Chagasic Cardiomyopathy.
Charcot-Marie-Tooth Disease
A Novel Mutation of the Membrane Metallo-Endopeptidase Gene Related to Late-Onset Hereditary Polyneuropathy: Case Report and Review of the Literature.
Cholangiocarcinoma
Overexpression of membrane metalloendopeptidase inhibits substance P-stimulation of cholangiocarcinoma growth.
Cholangiocarcinoma
Prognostic significance of the combined expression of neutral endopeptidase and dipeptidyl peptidase IV in intrahepatic cholangiocarcinoma patients after surgery resection.
Cholecystitis
Naloxone-reversible inhibition of gall-bladder mucosal fluid secretion in experimental cholecystitis in the cat by acetorphan, an enkephalinase inhibitor.
Cholecystitis, Acute
Naloxone-reversible inhibition of gall-bladder mucosal fluid secretion in experimental cholecystitis in the cat by acetorphan, an enkephalinase inhibitor.
Cholera
New drug targets for cholera therapy.
Cholestasis
Lack of hepatocellular CD10 along bile canaliculi is physiologic in early childhood and persistent in Alagille syndrome.
Cholestasis
Neutral endopeptidase activity is not elevated in serum in children with cholestatic liver disease: a unique role of aminopeptidase-m in sequential hydrolysis of peptides.
Cholesteatoma
Altered regulation of cell surface peptidases in human cholesteatoma.
Choriocarcinoma
Neutral endopeptidase/CD10 expression during phorbol ester-induced differentiation of choriocarcinoma cells through the protein kinase C- and extracellular signal-regulated kinase-dependent signalling pathway.
Choriocarcinoma
Signal pathway involved in increased expression of neutral endopeptidase 24.11 by gonadotropin releasing hormone in choriocarcinoma cells.
Choriocarcinoma
Upregulation of neutral endopeptidase expression and enzymatic activity during the differentiation of human choriocarcinoma cells.
Cluster Headache
A genome-wide analysis in cluster headache points to neprilysin and PACAP receptor gene variants.
Coinfection
A Strategy for Generating a Broad-Spectrum Monoclonal Antibody and Soluble Single-Chain Variable Fragments against Plant Potyviruses.
Coinfection
First Report of Tomato spotted wilt virus and Impatiens necrotic spot virus in Slovenia.
Coinfection
First report of Tomato spotted wilt virus and Impatiens necrotic spot virus in Slovenia.
Colitis
Anti-Inflammatory Effect of Homo- and Heterodimers of Natural Enkephalinase Inhibitors in Experimental Colitis in Mice.
Colitis
Anti-inflammatory effect of novel analogs of natural enkephalinase inhibitors in a mouse model of experimental colitis.
Colitis
Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P.
Colitis, Ulcerative
Expression of the common acute lymphoblastic leukaemia antigen (CALLA gp100) in the brush border of normal jejunum and jejunum of patients with coeliac disease.
Colitis, Ulcerative
Increase in substance P precursor mRNA in noninflamed small-bowel sections in patients with Crohn's disease.
Colitis, Ulcerative
Profound loss of neprilysin accompanied by decreased levels of neuropeptides and increased CRP in ulcerative colitis.
Colonic Neoplasms
Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands.
Colonic Neoplasms
Neutral endopeptidase (NEP) is differentially involved in biological activities and cell signaling of colon cancer cell lines derived from various stages of tumor development.
Colonic Neoplasms
Neutral endopeptidase depletion decreases colon cancer cell proliferation and TGF-?1 synthesis in indirect co-cultures with normal colon fibroblasts.
Colonic Neoplasms
Optimizing the Profile of [99mTc]Tc-NT(7-13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors.
Colorectal Neoplasms
Neutral endopeptidase (NEP) inhibitors - thiorphan, sialorphin, and its derivatives exert anti-proliferative activity towards colorectal cancer cells in vitro.
Complex Regional Pain Syndromes
Lack of genetic association of neutral endopeptidase (NEP) with complex regional pain syndrome (CRPS).
Confusion
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
Coronary Artery Disease
Soluble neprilysin and long-term clinical outcomes in patients with coronary artery disease undergoing percutaneous coronary intervention: a retrospective cohort study.
Coronary Disease
Effect of neutral endopeptidase inhibition on the actions of adrenomedullin and endothelin-1 in resistance arteries from patients with chronic heart failure.
Cough
Characterization of increased cough sensitivity after antigen challenge in guinea pigs.
Cough
Effect of Qinbai Qingfei Concentrated Pellets on substance P and neutral endopeptidase of rats with post-infectious cough.
Cough
Enzymatic modulation of bronchoconstriction, gland secretion, plasma extravasation and cough.
Cough
Evidence for substance P as an endogenous substance causing cough in guinea pigs.
Cough
Inhalation of phosphoramidon, a neutral endopeptidase inhibitor, induces cough in awake guinea-pigs.
Cough
Neutral endopeptidase inhibitors potentiate substance P- and capsaicin-induced cough in awake guinea pigs.
Cough
Pharmacology of bradykinin evoked coughing in guinea pigs.
Cough
Recombinant human enkephalinase (neutral endopeptidase) prevents cough induced by tachykinins in awake guinea pigs.
COVID-19
Broadening COVID-19 Interventions to Drug Innovation: Neprilysin Pathway as a Friend, Foe, or Promising Molecular Target?
COVID-19
Corrigendum to "Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost" [Biochem. Pharmacol. 178 (2020) 114057].
COVID-19
Neprilysin Inhibitors and Angiotensin(1-7) in COVID-19.
COVID-19
New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19.
COVID-19
Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost.
COVID-19
The Controversy of Renin-Angiotensin-System Blocker Facilitation Versus Countering COVID-19 Infection.
COVID-19
The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.
COVID-19
The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19.
Crohn Disease
Expression of the common acute lymphoblastic leukaemia antigen (CALLA gp100) in the brush border of normal jejunum and jejunum of patients with coeliac disease.
Crohn Disease
Increase in substance P precursor mRNA in noninflamed small-bowel sections in patients with Crohn's disease.
Cushing Syndrome
Significance of renal kininases in patients with Cushing's syndrome.
Cystic Fibrosis
A comprehensive review of therapeutic approaches available for the treatment of cholera.
Cystic Fibrosis
New drug targets for cholera therapy.
Cystitis, Interstitial
Activation of the kallikrein kinin system in interstitial cystitis.
Cytomegalovirus Infections
The etiology of congenital nephrotic syndrome: current status and challenges.
Death, Sudden, Cardiac
Sacubitril/Valsartan: potential treatment for paediatric heart failure.
Dehydration
Combined effects of water stress and high temperature on photosynthesis, nitrogen metabolism and lipid peroxidation of a perennial grass Leymus chinensis.
Dementia
Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database.
Dementia
Neprilysin Activity in Cerebrospinal Fluid is Associated with Dementia and Amyloid-?42 Levels in Lewy Body Disease.
Dementia
Neprylisin decreases uniformly in Alzheimer's disease and in normal aging.
Dementia
Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia.
Dementia
Rare Variants in MME, Encoding Metalloprotease Neprilysin, Are Linked to Late-Onset Autosomal-Dominant Axonal Polyneuropathies.
Dementia
Transducible P11-CNTF rescues the learning and memory impairments induced by amyloid-beta peptide in mice.
Dermatitis, Allergic Contact
Neutral endopeptidase terminates substance P-induced inflammation in allergic contact dermatitis.
Diabetes Complications
Altered cardiac bradykinin metabolism in experimental diabetes caused by the variations of angiotensin-converting enzyme and other peptidases.
Diabetes Complications
Neprilysin inhibition: a new therapeutic option for type 2 diabetes?
Diabetes Mellitus
Current indications of plasma atrial natriuretic peptide measurements in human diseases.
Diabetes Mellitus
Degradation of islet amyloid polypeptide by neprilysin.
Diabetes Mellitus
Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.
Diabetes Mellitus
Effect of high glucose levels on amyloid ? production in retinas of spontaneous diabetes mellitus Otsuka Long-Evans Tokushima fatty rats.
Diabetes Mellitus
New drugs: big changes in conservative heart failure therapy?
Diabetes Mellitus, Type 1
Brain-Wide Insulin Resistance, Tau Phosphorylation Changes, and Hippocampal Neprilysin and Amyloid-? Alterations in a Monkey Model of Type 1 Diabetes.
Diabetes Mellitus, Type 1
Early loss of innervation of cornea epithelium in streptozotocin-induced type 1 diabetic rats: improvement with ilepatril treatment.
Diabetes Mellitus, Type 1
Effect of treatment of high fat fed/low dose streptozotocin-diabetic rats with Ilepatril on vascular and neural complications.
Diabetes Mellitus, Type 1
Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats.
Diabetes Mellitus, Type 2
Degradation of islet amyloid polypeptide by neprilysin.
Diabetes Mellitus, Type 2
Effect of inhibition of angiotensin converting enzyme and/or neutral endopeptidase on vascular and neural complications in high fat fed/low dose streptozotocin-diabetic rats.
Diabetes Mellitus, Type 2
Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.
Diabetes Mellitus, Type 2
Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial.
Diabetes Mellitus, Type 2
Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels.
Diabetes Mellitus, Type 2
Neprilysin Deficiency Protects Against Fat-Induced Insulin Secretory Dysfunction by Maintaining Calcium Influx.
Diabetes Mellitus, Type 2
Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner.
Diabetes Mellitus, Type 2
Neprilysin inhibition: a new therapeutic option for type 2 diabetes?
Diabetes Mellitus, Type 2
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Diabetes Mellitus, Type 2
The Drosophila melanogaster Neprilysin Nepl15 is involved in lipid and carbohydrate storage.
Diabetic Cardiomyopathies
Histone Acetylation Regulates Natriuretic Peptides and Neprilysin Gene Expressions in Diabetic Cardiomyopathy and Nephropathy.
Diabetic Cardiomyopathies
Simultaneous inhibition of neprilysin and activation of ACE2 prevented diabetic cardiomyopathy.
Diabetic Cardiomyopathies
Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats.
Diabetic Nephropathies
Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy.
Diabetic Nephropathies
Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.
Diabetic Nephropathies
Genetic and functional effects of membrane metalloendopeptidase on diabetic nephropathy development.
Diabetic Nephropathies
Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension.
Diabetic Nephropathies
Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in db/db mice and KKAy mice compared with valsartan treatment.
Diabetic Nephropathies
The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy.
Diabetic Nephropathies
Urinary Proteome Analysis Identified Neprilysin and VCAM as Proteins Involved in Diabetic Nephropathy.
Diabetic Neuropathies
The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine experimental diabetic neuropathy.
Diabetic Retinopathy
Elevated neprilysin activity in vitreous of patients with proliferative diabetic retinopathy.
Diabetic Retinopathy
The changing features of serum adropin, copeptin, neprilysin and chitotriosidase which are associated with vascular endothelial function in type 2 diabetic retinopathy patients.
Down Syndrome
Accumulation of Insoluble Amyloid-? in Down's Syndrome is Associated with Increased BACE-1 and Neprilysin Activities.
Down Syndrome
Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques.
Drug-Related Side Effects and Adverse Reactions
Diarrhoea with the angiotensin receptor neprilysin inhibitor sacubitril?+?valsartan: A pharmacovigilance study.
Dyslipidemias
Key advances in clinical cardiology.
Dyslipidemias
Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease.
Dyspnea
BNP and NT-proBNP Interpretation in the Neprilysin Inhibitor Era.
Dyspnea
Tachykinin-induced dyspnea in conscious guinea pigs.
Endometrial Neoplasms
Decreased expression of messenger RNAs encoding endothelin receptors and neutral endopeptidase 24.11 in endometrial cancer.
Endometrial Neoplasms
Imbalance between neutral endopeptidase 24.11 and endothelin-1 expression in human endometrial carcinoma.
Endometriosis
Expression of aminopeptidase N and neutral endopeptidase on the endometrial stromal cells in endometriosis and adenomyosis.
Enteritis
Deletion of neutral endopeptidase exacerbates intestinal inflammation induced by Clostridium difficile toxin A.
Epilepsy
Possible long-lasting inhibition of converting enzyme by enalapril in human cerebrospinal fluid.
Epilepsy
The levels of renin-angiotensin related components are modified in the hippocampus of rats submitted to pilocarpine model of epilepsy.
Epstein-Barr Virus Infections
Induction of differentiation of African Burkitt's lymphoma cells by phorbol ester: possible relation with early B cells.
Esophageal Squamous Cell Carcinoma
Membrane Metalloendopeptidase (MME) Suppresses Metastasis of Esophageal Squamous Cell Carcinoma (ESCC) by Inhibiting FAK-RhoA Signaling Axis.
Essential Hypertension
Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans.
Essential Hypertension
Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension.
Essential Hypertension
Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension.
Essential Hypertension
Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension.
Essential Hypertension
Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II.
Essential Hypertension
Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
Essential Hypertension
Dietary sodium and inhibition of neutral endopeptidase 24.11 in essential hypertension.
Essential Hypertension
Enkephalinase (EC 3.4.24.11) inhibitors: protection of endogenous ANF against inactivation and potential therapeutic applications.
Essential Hypertension
Increased tissue neutral endopeptidase 24.11 activity in spontaneously hypertensive hamsters.
Essential Hypertension
Inhibition of endopeptidase EC 3.4.24.11 by candoxatril lowered blood pressure and increased urinary but not plasma atrial natriuretic peptide in essential hypertension.
Essential Hypertension
Neprilysin Inhibitors and Bradykinin.
Essential Hypertension
Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension.
Essential Hypertension
Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan.
Familial Hypophosphatemic Rickets
cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone.
Familial Hypophosphatemic Rickets
Cloning and sequencing of human PEX from a bone cDNA library: evidence for its developmental stage-specific regulation in osteoblasts.
Familial Hypophosphatemic Rickets
New insights into the pathogenesis of inherited phosphate wasting disorders.
Fibroadenoma
Glial fibrillary acidic protein immunoreactivity in normal and diseased human breast.
Gallstones
Evidence for oxidative stress in the gall bladder mucosa of gall stone patients.
Gastritis
Differential changes in Substance P, VIP as well as neprilysin levels in patients with gastritis or ulcer.
Gastritis, Atrophic
Common acute lymphoplastic leukemia antigen (CALLA) and intestinal metaplasia.
Gastroenteritis
Towards a human rotavirus disease model.
Gastrointestinal Diseases
Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders.
Gestational Trophoblastic Disease
The expression and localization of neutral endopeptidase 24.11/CD10 in human gestational trophoblastic diseases.
Glioblastoma
CD10 and CD44 genes of leukemic cells and malignant cell lines show no evidence of transformation-related alterations.
Glioblastoma
Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells.
Glioma
Activation of 5-HT2C Receptor Promotes the Expression of Neprilysin in U251 Human Glioma Cells.
Glioma
Expression of cALLa/NEP on gliomas: a possible marker of malignancy.
Glioma
Expression of HLA-DR and common acute lymphoblastic leukemia antigens on glioma cells.
Glioma
Human glioma cell lines expressing the common acute lymphoblastic leukemia antigen (cALLa) have neutral endopeptidase activity.
Glioma
Involvement of endopeptidase-24.11 in degradation of substance P by glioma cells.
Glomerulonephritis
Common acute lymphoblastic leukemia antigen expression on visceral epithelial cells in several types of glomerulonephritis.
Glomerulonephritis
The Comparison of the Podocyte Expression of Synaptopodin, CR1 and Neprilysin in Human Glomerulonephritis: Could the Expression of CR1 be Clinically Relevant?
Glomerulonephritis
[The role of podocytes in normal glomerular function and in the pathogenesis of glomerulonephritis. Part II. Phenotypic and functional changes of podocytes in glomerulonephritis]
Glomerulonephritis, Membranous
ADVANCES IN MEMBRANOUS NEPHROPATHY : SUCCESS STORIES OF A LONG JOURNEY.
Glomerulonephritis, Membranous
Anti-neutral endopeptidase, natriuretic peptides disarrangement, and proteinuria onset in membranous nephropathy.
Glomerulonephritis, Membranous
Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy.
Glomerulonephritis, Membranous
Computational prediction and experimental assessment of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from neutral endopeptidase.
Glomerulonephritis, Membranous
Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies.
Glomerulonephritis, Membranous
Hereditary axonal neuropathy related to MME gene mutation in a family with fetomaternal alloimmune glomerulonephritis.
Glomerulonephritis, Membranous
Lessons from a rare disease: IgG subclass and disease severity in alloimmune antenatal membranous nephropathy.
Glomerulonephritis, Membranous
Mechanisms of disease: Alloimmunization in renal diseases.
Glomerulonephritis, Membranous
Mechanisms of immune-deposit formation and the mediation of immune renal injury.
Glomerulonephritis, Membranous
Membranous glomerulopathy: the evolving story.
Glomerulonephritis, Membranous
New insights into the pathogenesis of membranous glomerulonephritis.
Glomerulonephritis, Membranous
Pathogenesis of membranous nephropathy: recent advances and future challenges.
Glomerulonephritis, Membranous
Pathophysiological advances in membranous nephropathy: time for a shift in patient's care.
Glomerulonephritis, Membranous
Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies.
Glomerulonephritis, Membranous
Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men.
Glomerulonephritis, Membranous
[Anti-CD10 fetomaternal alloimmunisation]
Glomerulonephritis, Membranous
[Idiopathic and secondary membranous nephropathies].
Glomerulonephritis, Membranous
[The involvement of neprilysin in the pathogenesis of glomerulopathies]
Glucose Intolerance
Hypertension up to date: SPRINT to SPYRAL.
Gram-Negative Bacterial Infections
Lipopolysaccharide induces upregulation of neutral endopeptidase 24.11 on human neutrophils: involvement of the CD14 receptor.
Heart Diseases
Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs.
Heart Failure
? Sacubitril valsartan for heart failure.
Heart Failure
A Novel Paradigm for Sacubitril/Valsartan: Beta-Endorphin Elevation as a Contributor to Exercise Tolerance Improvement in Rats With Preexisting Heart Failure Induced by Pressure Overload.
Heart Failure
A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study.
Heart Failure
A Test in Context: Neprilysin: Function, Inhibition, and Biomarker.
Heart Failure
Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure.
Heart Failure
Acute and chronic neutral endopeptidase inhibition in rats with aortocaval shunt.
Heart Failure
Acute hemodynamic, hormonal, and renal effects of neutral endopeptidase inhibition in ovine heart failure.
Heart Failure
Acute natriuretic effect of fasidotrilat, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in rats with heart failure.
Heart Failure
Altered serum levels of neprilysin in heart failure patients with reduced ejection fraction.
Heart Failure
Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.
Heart Failure
Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results.
Heart Failure
Angiotensin 2 Type 1 Receptor Blockade with Neprilysin Inhibition for Chronic Heart Failure: A New Paradigm?
Heart Failure
Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure.
Heart Failure
Angiotensin Neprilysin Inhibition for Patients With Heart Failure: What If Sacubitril/Valsartan Were a Treatment for Cancer?
Heart Failure
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
Heart Failure
Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact.
Heart Failure
Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial.
Heart Failure
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Heart Failure
Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe.
Heart Failure
Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
Heart Failure
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation: The PRIME Study.
Heart Failure
Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
Heart Failure
Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR).
Heart Failure
Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series.
Heart Failure
Angiotensin Receptor Neprilysin Inhibitor in Japanese Patients With Heart Failure and Reduced Ejection Fraction?- Baseline Characteristics and Treatment of PARALLEL-HF Trial.
Heart Failure
Angiotensin receptor neprilysin inhibitors in older patients with heart failure.
Heart Failure
Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension.
Heart Failure
Angiotensin Receptor-Neprilysin Inhibition.
Heart Failure
Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis.
Heart Failure
Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure.
Heart Failure
Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects.
Heart Failure
Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: implications for novel therapeutic strategies.
Heart Failure
Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure.
Heart Failure
Barcelona Bio-HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization.
Heart Failure
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
Heart Failure
Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.
Heart Failure
Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure.
Heart Failure
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Heart Failure
Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure: A Review.
Heart Failure
Biological and In silico Studies on Synthetic Analogues of Tyrosine Betaine as Inhibitors of Neprilysin - A Drug Target for the Treatment of Heart Failure.
Heart Failure
BNP and NT-proBNP Interpretation in the Neprilysin Inhibitor Era.
Heart Failure
Calcitonin gene-related peptide is not elevated in rat plasma by heart failure or by neutral endopeptidase inhibition.
Heart Failure
Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition.
Heart Failure
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
Heart Failure
Cardiac foetal reprogramming: a tool to exploit novel treatment targets for the failing heart.
Heart Failure
Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts.
Heart Failure
Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure.
Heart Failure
Cardiovascular effects of natriuretic peptides and their interrelation with endothelin-1.
Heart Failure
Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
Heart Failure
Case of a patient with heart failure, dilated cardiomyopathy and atrial fibrillation treated with sacubitril/valsartan.
Heart Failure
Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy.
Heart Failure
Changes in QRS Duration Are Associated with a Therapeutic Response to Sacubitril-valsartan in Heart Failure with Reduced Ejection Fraction.
Heart Failure
Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.
Heart Failure
Chronic heart failure: what does the horizon look like?
Heart Failure
Chronic kidney disease, heart failure and neprilysin inhibition.
Heart Failure
Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
Heart Failure
Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction.
Heart Failure
Circulating Neprilysin Level Predicts the Risk of Cardiovascular Events in Hemodialysis Patients.
Heart Failure
Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism.
Heart Failure
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor I: assay in plasma of human volunteers by atmospheric-pressure ionisation mass-spectrometry following derivatisation with BF3-methanol.
Heart Failure
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor II: assay in the plasma and urine of human volunteers by dissociation enhanced lanthanide fluorescence immunoassay (DELFIA).
Heart Failure
Cognitive performance of patients with chronic heart failure on sacubitril/valsartan : A retrospective cohort study.
Heart Failure
Combined angiotensin receptor and neprilysin inhibition therapy for heart failure.
Heart Failure
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Heart Failure
Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure.
Heart Failure
Combined Inhibition of the Renin-Angiotensin System and Neprilysin Positively Influences Complex Mitochondrial Adaptations in Progressive Experimental Heart Failure.
Heart Failure
Combined Neprilysin and RAS Inhibition in Cardiovascular Diseases: A Review of Clinical Studies.
Heart Failure
Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
Heart Failure
Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis.
Heart Failure
Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II.
Heart Failure
Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure.
Heart Failure
Comparison of 12-month kinetics of serum markers of fibrosis between treatment with angiotensin receptor neprilysin inhibitor (ARNI) and angiotensin converting enzyme inhibitor (ACE-I) in patients with heart failure with reduced ejection fraction.
Heart Failure
Comparison of chronic neutral endopeptidase inhibition and furosemide in an ovine model of heart failure.
Heart Failure
Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF).
Heart Failure
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
Heart Failure
Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure.
Heart Failure
Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure.
Heart Failure
Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
Heart Failure
Concurrent neutral endopeptidase and ACE inhibition in experimental heart failure: renal and hormonal effects.
Heart Failure
Conflicting Perspectives on the Value of Neprilysin Inhibition in Heart Failure Revealed During Development of a Decision Aid Focusing on Patient Costs for Sacubitril/Valsartan.
Heart Failure
Correction.
Heart Failure
Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines.
Heart Failure
Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction.
Heart Failure
Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
Heart Failure
Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea.
Heart Failure
Critical angioedema induced by a renin angiotensin system blocker in the contemporary era of increasing heart failure: A case report and commentary.
Heart Failure
Current role of neprilysin inhibitors in hypertension and heart failure.
Heart Failure
Current trends and future perspectives for heart failure treatment leveraging cGMP modifiers and the practical effector PKG.
Heart Failure
Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
Heart Failure
Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
Heart Failure
Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy.
Heart Failure
Detection of Neprilysin-Derived BNP Fragments in the Circulation: Possible Insights for Targeted Neprilysin Inhibition Therapy for Heart Failure.
Heart Failure
Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter.
Heart Failure
Direct inhibition of neutral endopeptidase in vasopeptidase inhibitor-mediated amelioration of cardiac remodeling in rats with chronic heart failure.
Heart Failure
Do plasma neprilysin activity and plasma neprilysin concentration predict cardiac events in chronic kidney disease patients?
Heart Failure
Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
Heart Failure
Dose-ranging effects of candoxatril on elimination of exogenous atrial natriuretic peptide in chronic heart failure.
Heart Failure
Drosophila Neprilysins Are Involved in Middle-Term and Long-Term Memory.
Heart Failure
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
Heart Failure
Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
Heart Failure
Dual-Acting Angiotensin Receptor-Neprilysin Inhibition.
Heart Failure
Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure.
Heart Failure
Effect of 24-hour blood pressure and heart rate on the prognosis of patients with reduced and midrange LVEF.
Heart Failure
Effect of food on the oral bioavailability of the angiotensin receptor - neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects?.
Heart Failure
Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
Heart Failure
Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.
Heart Failure
Effect of neutral endopeptidase inhibition on the actions of adrenomedullin and endothelin-1 in resistance arteries from patients with chronic heart failure.
Heart Failure
Effect of neutral endopeptidase inhibitor in rats with congestive heart failure.
Heart Failure
Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor.
Heart Failure
Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure.
Heart Failure
Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor.
Heart Failure
Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
Heart Failure
Effects of angiotensin receptor neprilysin inhibition on P-wave dispersion in heart failure with reduced ejection fraction.
Heart Failure
Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
Heart Failure
Effects of angiotensin receptor neprilysin inhibitor on renal function in patients with heart failure: a systematic review and meta-analysis.
Heart Failure
Effects of Angiotensin-Neprilysin Inhibition in Canines with Experimentally Induced Cardiorenal Syndrome.
Heart Failure
Effects of atriopeptidase inhibitor UK 79300 on left ventricular hydraulic load in patients with congestive heart failure.
Heart Failure
Effects of chronic neutral endopeptidase inhibition on the progression of left ventricular dysfunction and remodeling in dogs with moderate heart failure.
Heart Failure
Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure.
Heart Failure
Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat.
Heart Failure
Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Heart Failure
Effects of omapatrilat on hemodynamics and safety in patients with heart failure.
Heart Failure
Effects of omapatrilat on systemic arterial function in patients with chronic heart failure.
Heart Failure
Effects of optimized heart failure medication on central sleep apnea with Cheyne-Stokes respiration pattern in chronic heart failure with reduced left-ventricular ejection fraction.
Heart Failure
Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure.
Heart Failure
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
Heart Failure
Effects of sacubitril/valsartan on B-type natriuretic peptide circulating levels and loop diuretic dose in a case series of stabilized heart failure patients with left ventricular ejection fraction ?35.
Heart Failure
Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
Heart Failure
Efficacy and safety of combined neprilysin and RAS inhibition in heart failure: A meta-analysis of randomized controlled trials.
Heart Failure
Efficacy and safety of combined neprilysin and RAS inhibition in heart failure: Let's leave the doubts behind.
Heart Failure
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.
Heart Failure
Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction?- Results From the PARALLEL-HF Study.
Heart Failure
Efficacy and safety of sacubitril/valsartan in the treatment of heart failure: protocol for a systematic review incorporating unpublished clinical study reports.
Heart Failure
Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure.
Heart Failure
Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
Heart Failure
Enhanced endothelin-1 degradation by intravenous morphine in patients with congestive heart failure: role of neutral endopeptidase 24.11.
Heart Failure
Enkephalinase (EC 3.4.24.11) inhibitors: protection of endogenous ANF against inactivation and potential therapeutic applications.
Heart Failure
Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure.
Heart Failure
Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure.
Heart Failure
Entresto, a new Panacea for Heart Failure?
Heart Failure
Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Heart Failure
European drug market entries 2015 with new mechanisms of action.
Heart Failure
Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease.
Heart Failure
Evolution of natriuretic peptide biomarkers in heart failure: Implications for clinical care and clinical trials.
Heart Failure
First-in-Class Angiotensin Receptor Neprilysin Inhibitor in Heart Failure.
Heart Failure
First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice.
Heart Failure
From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5).
Heart Failure
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
Heart Failure
From kinetics to dynamics: are there differences between ACE inhibitors?
Heart Failure
Future pharmacological therapy in hypertension.
Heart Failure
Heart failure augments the cardiovascular and renal effects of neutral endopeptidase inhibition in rats.
Heart Failure
Heart failure with preserved ejection fraction: A dilemma in treatment options.
Heart Failure
Heart Failure With Reduced Ejection Fraction Is Characterized by Systemic NEP Downregulation.
Heart Failure
Heart failure.
Heart Failure
Heart failure: Neprilysin inhibition attenuates risk of hyperkalaemia in HFrEF.
Heart Failure
How does neprilysin inhibition in heart failure work?
Heart Failure
Hypertension - state of the art 2015.
Heart Failure
IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure.
Heart Failure
Impact of Patient and Model of Care Factors on Titration and Tolerability of Sacubitril/Valsartan: An Early Australian Real-World Experience.
Heart Failure
Impact of prolonged utilization of neprilysin inhibition on the cognitive function of heart failure patients.
Heart Failure
Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date.
Heart Failure
Impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction.
Heart Failure
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).
Heart Failure
Increased circulating atrial natriuretic factor concentrations in patients with chronic heart failure after inhibition of neutral endopeptidase: effects on diastolic function.
Heart Failure
Increased expression of renal neutral endopeptidase in severe heart failure.
Heart Failure
Increased granulocyte membrane neprilysin (CD10) expression is associated with better prognosis in heart failure.
Heart Failure
Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
Heart Failure
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Heart Failure
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
Heart Failure
Influence of physician networks on prescribing a new ingredient combination in heart failure: a longitudinal claim data-based study.
Heart Failure
Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial.
Heart Failure
Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
Heart Failure
Inhibition of neutral endopeptidase 3.4.24.11 in conscious dogs with pacing induced heart failure.
Heart Failure
Inhibition of thermolysin and neutral endopeptidase 24.11 by a novel glutaramide derivative: X-ray structure determination of the thermolysin-inhibitor complex.
Heart Failure
Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Heart Failure
Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Heart Failure
Interaction Between Sacubitril and Valsartan in Preventing Heart Failure Induced by Aortic Valve Insufficiency in Rats.
Heart Failure
Intrarenal effects of ecadotril during acute volume expansion in dogs with congestive heart failure.
Heart Failure
Is Entresto good for the brain?
Heart Failure
It Is Not Taboo: Addressing Sexual Function in Adults with Congenital Heart Disease.
Heart Failure
Key advances in clinical cardiology.
Heart Failure
Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure.
Heart Failure
Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators.
Heart Failure
LCZ696 ameliorates lipopolysaccharide-induced endothelial injury.
Heart Failure
LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy.
Heart Failure
Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity.
Heart Failure
Long-term treatment with neutral endopeptidase inhibitor improves cardiac function and reduces natriuretic peptides in rats with chronic heart failure.
Heart Failure
Management of Heart Failure Patient with CKD.
Heart Failure
Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
Heart Failure
Medical Therapy of Heart Failure with Reduced Ejection Fraction-A Call for Comparative Research.
Heart Failure
Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
Heart Failure
Moderate potassium lowering effect of exogenous atrial natriuretic peptide in patients with acute heart failure.
Heart Failure
Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge?
Heart Failure
Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP.
Heart Failure
Natriuretic peptide-potentiating actions of neutral endopeptidase inhibition in rats with experimental heart failure.
Heart Failure
Natriuretic peptides and neprilysin inhibition in hypertension and hypertensive organ damage.
Heart Failure
Neprilysin and Heart Failure: A "Sympathetic" Relationship?
Heart Failure
Neprilysin and Natriuretic Peptide Regulation in Heart Failure.
Heart Failure
Neprilysin as a Biomarker: Challenges and Opportunities.
Heart Failure
Neprilysin in Heart Failure: From Oblivion to Center Stage.
Heart Failure
Neprilysin Inhibition and the Treatment of Heart Failure: Recent Steps in the Right Direction.
Heart Failure
Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy.
Heart Failure
Neprilysin inhibition does not alter dynamic of proenkephalin-A 119-159 and pro-substance P in heart failure.
Heart Failure
Neprilysin inhibition for heart failure.
Heart Failure
Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.
Heart Failure
Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides.
Heart Failure
Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism.
Heart Failure
Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
Heart Failure
Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
Heart Failure
Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study.
Heart Failure
Neprilysin inhibition--a novel therapy for heart failure.
Heart Failure
Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions.
Heart Failure
Neprilysin inhibition: a new therapeutic option for type 2 diabetes?
Heart Failure
Neprilysin Inhibitors and Bradykinin.
Heart Failure
Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease.
Heart Failure
Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease. Response to the letter of Siniorakis et al.
Heart Failure
Neprilysin inhibitors preserve renal function in heart failure.
Heart Failure
Neprilysin Inhibitors: Emerging Therapy for Heart Failure.
Heart Failure
Neprilysin Inhibitors: Filling a Gap in Heart Failure Management, Albeit Amidst Controversy and at a Significant Cost.
Heart Failure
Neprilysin Plasma Concentrations: A New Prognostic Marker in Heart Failure.
Heart Failure
Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?
Heart Failure
Neprilysin: Biotarget and Biomarker in Heart Failure.
Heart Failure
Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure.
Heart Failure
Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition.
Heart Failure
Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure.
Heart Failure
Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure.
Heart Failure
New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11.
Heart Failure
New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension.
Heart Failure
New pharmacotherapy for heart failure with reduced ejection fraction.
Heart Failure
New therapies for the treatment of congestive heart failure.
Heart Failure
New thiol inhibitors of neutral endopeptidase EC 3.4.24.11: synthesis and enzyme active-site recognition.
Heart Failure
Novel therapies in acute and chronic heart failure.
Heart Failure
NT-proCNP And CNP Do Not Correlate In Patients With Chagas' Disease: Role For Neutral Endopeptidase.
Heart Failure
Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.
Heart Failure
Omapatrilat. Bristol-Myers Squibb.
Heart Failure
Omapatrilat: penetration across the blood-brain barrier and effects on ischaemic stroke in rats.
Heart Failure
Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
Heart Failure
Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240.
Heart Failure
Paramount Importance of Angiotensin Receptor Neprilysin Inhibitor in Heart Failure Management.
Heart Failure
Pathophysiology of congestive heart failure: role of atrial natriuretic factor and therapeutic implications.
Heart Failure
Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Chronic Heart Failure.
Heart Failure
Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor.
Heart Failure
Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol.
Heart Failure
Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
Heart Failure
Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects.
Heart Failure
Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).
Heart Failure
Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects.
Heart Failure
Pharmacology of heart failure: From basic science to novel therapies.
Heart Failure
PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction.
Heart Failure
PL 03-3 THE FUTURE DEVELOPMENT OF DRUG THERAPY FOR HYPERTENSION.
Heart Failure
Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure.
Heart Failure
Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF.
Heart Failure
Plasma soluble neprilysin levels are unchanged during recovery after decompensation of heart failure: a matter of the magnitude of the changes in systemic haemodynamics?
Heart Failure
Potential and Limitations of Atrial Natriuretic Peptide as Biomarker in Pediatric Heart Failure-A Comparative Review.
Heart Failure
Potential Expanded Indications for Neprilysin Inhibitors.
Heart Failure
Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure.
Heart Failure
Potential role of mixed ACE and neutral endopeptidase inhibitor in the treatment of heart failure.
Heart Failure
Potentiation of brain natriuretic peptides by SQ 28,603, an inhibitor of neutral endopeptidase 3.4.24.11, in monkeys and rats.
Heart Failure
Practical considerations on the introduction of sacubitril/valsartan in clinical practice: Current evidence and early experience.
Heart Failure
Prognostic Value and Kinetics of Soluble Neprilysin in Acute Heart Failure: A Pilot Study.
Heart Failure
Prolonged neutral endopeptidase inhibition in heart failure.
Heart Failure
Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan.
Heart Failure
Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
Heart Failure
Pulmonary and renal neutral endopeptidase EC 3.4.24.11 in rats with experimental heart failure.
Heart Failure
Pulmonary and urinary clearance of atrial natriuretic factor in acute congestive heart failure in dogs.
Heart Failure
Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling.
Heart Failure
Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study.
Heart Failure
Reduced ejection fraction heart failure - new data from multicenter studies and national registries regarding general and elderly populations: hopes and disappointments.
Heart Failure
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.
Heart Failure
Renal protective effect of sacubitril/valsartan in patients with heart failure.
Heart Failure
Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure.
Heart Failure
Renal response to candoxatrilat in patients with heart failure.
Heart Failure
Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure.
Heart Failure
Reversal of heart failure in a chemogenetic model of persistent cardiac redox stress.
Heart Failure
Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials.
Heart Failure
Role of Neprilysin Inhibitors in Heart Failure.
Heart Failure
Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure.
Heart Failure
Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients.
Heart Failure
Sacubitril/Valsartan (Entresto®)-Induced Hyponatremia.
Heart Failure
Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
Heart Failure
Sacubitril/Valsartan Improves Left Ventricular Function in Chronic Pressure Overload Independent of Intact Cyclic Guanosine Monophosphate-dependent Protein Kinase I Alpha Signaling.
Heart Failure
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.
Heart Failure
Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction.
Heart Failure
Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect.
Heart Failure
Sacubitril/Valsartan to Treat Heart Failure in a Patient with Relapsing Hairy Cell Leukaemia: Case Report.
Heart Failure
Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in db/db mice and KKAy mice compared with valsartan treatment.
Heart Failure
Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
Heart Failure
Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
Heart Failure
Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment.
Heart Failure
Sacubitril/valsartan: from a large clinical trial to clinical practice.
Heart Failure
Sacubitril/Valsartan: From Clinical Trials to Real-world Experience.
Heart Failure
Sacubitril/Valsartan: potential treatment for paediatric heart failure.
Heart Failure
Sacubitrilat reduces pro-arrhythmogenic sarcoplasmic reticulum Ca2+ leak in human ventricular cardiomyocytes of patients with end-stage heart failure.
Heart Failure
Safety, Pharmacokinetics, and Pharmacodynamics of TD-0714, a Novel Potent Neprilysin Inhibitor in Healthy Adult and Elderly Subjects.
Heart Failure
Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure.
Heart Failure
Serum neprilysin and recurrent hospitalizations after acute heart failure.
Heart Failure
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Heart Failure
SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis.
Heart Failure
Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors?
Heart Failure
Short-term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril/valsartan.
Heart Failure
Should Angiotensin Receptor Neprilysin Inhibitors Replace Angiotensin-converting Enzyme Inhibitors in Heart Failure With a Reduced Ejection Fraction?
Heart Failure
Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization.
Heart Failure
Soluble Neprilysin and Corin Concentrations in Relation to Clinical Outcome in Chronic Heart Failure.
Heart Failure
Soluble neprilysin and long-term clinical outcomes in patients with coronary artery disease undergoing percutaneous coronary intervention: a retrospective cohort study.
Heart Failure
Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction.
Heart Failure
Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction?
Heart Failure
Soluble neprilysin does not correlate with prognosis in pulmonary hypertension.
Heart Failure
Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease.
Heart Failure
Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients.
Heart Failure
Soluble neprilysin retains catalytic activity in heart failure.
Heart Failure
Soluble Neprilysin, Corin Concentrations, and Clinical Outcome in Chronic Heart Failure: The miRNAs Role.
Heart Failure
Soluble neprilysin, NT-proBNP, and growth differentiation factor-15 as biomarkers for heart failure in dialysis patients (SONGBIRD).
Heart Failure
Soluble neprilysin: A versatile biomarker for heart failure, cardiovascular diseases and diabetic complications-A systematic review.
Heart Failure
Soluble Neprilysin?- Cardiac Function and Outcome in Hypertrophic Cardiomyopathy.
Heart Failure
Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
Heart Failure
Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin Inhibitors.
Heart Failure
Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure.
Heart Failure
Switching from ramipril to sacubitril/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction.
Heart Failure
Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure.
Heart Failure
Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.
Heart Failure
Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure.
Heart Failure
The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics.
Heart Failure
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Heart Failure
The atriopeptidase inhibitor UK 69,578 increases atrial natriuretic factor and causes a natriuresis in normal humans.
Heart Failure
The case for inhibiting p38 mitogen-activated protein kinase in heart failure.
Heart Failure
The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure.
Heart Failure
The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-? concentrations and clearance in the cynomolgus monkey.
Heart Failure
The effect of LCZ696 on amyloid-? concentrations in cerebrospinal fluid in healthy subjects.
Heart Failure
The effects of adding angiotensin receptor neprilysin inhibitors to usual care in patients with heart failure: a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.
Heart Failure
The Effects of LCZ696 in Patients With Hypertension Compared With Angiotensin Receptor Blockers: A Meta-Analysis of Randomized Controlled Trials.
Heart Failure
The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin.
Heart Failure
The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations.
Heart Failure
The Initial Evaluation and Management of a Patient with Heart Failure.
Heart Failure
The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
Heart Failure
The PARADIGM of ARNI's: Assessing reasons for non-implementation in heart failure.
Heart Failure
The Path to an Angiotensin Receptor Antagonist-Neprilysin Inhibitor in the Treatment of Heart Failure.
Heart Failure
The potential role of valsartan + AHU377 ( LCZ696 ) in the treatment of heart failure.
Heart Failure
The Role of Neprilysin Inhibitors in the Treatment of Heart Failure with Preserved Ejection Fraction.
Heart Failure
The role of neurohormonal activation in chronic heart failure and postmyocardial infarction.
Heart Failure
The role of neutral endopeptidase in dogs with evolving congestive heart failure.
Heart Failure
The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
Heart Failure
The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
Heart Failure
The safety of sacubitril-valsartan for the treatment of chronic heart failure.
Heart Failure
Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II-Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension.
Heart Failure
Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition.
Heart Failure
Treatment with angiotensin receptor neprilysin inhibitor for Taiwan heart failure patients: Rationale and baseline characteristics of the TAROT-HF study.
Heart Failure
Update in recent clinical trials in heart failure.
Heart Failure
Use of Angiotensin Receptor Neprilysin Inhibitor in Patients on Maintenance Hemodialysis with Reduced Cardiac Ejection Fraction, Real-World Experience From a Single Center.
Heart Failure
Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
Heart Failure
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
Heart Failure
Vasopeptidase inhibitors: will they have a role in clinical practice?
Heart Failure
Was the Enalapril Dose Too Low in the PARADIGM-HF Trial?
Heart Failure
What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines.
Heart Failure
[A novel therapy option for heart failure with dual angiotensin receptor and neprilysin inhibition].
Heart Failure
[ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].
Heart Failure
[Bradykinin and ventricular function]
Heart Failure
[Diuretics in the treatment of heart failure: current pathophysiological aspects]
Heart Failure
[First Experience of Clinical Application of LCZ696 an AT1-angiotensin Receptors and Neprilysin Inhibitor in Patients With Chronic Heart Failure and Reduced Ejection Fraction].
Heart Failure
[First Experience of Clinical Application of LCZ696--an AT1-angiotensin Receptors and Neprilysin Inhibitor--in Patients With Chronic Heart Failure and Reduced Ejection Fraction].
Heart Failure
[From basic research to clinical results. The OVERTURE, ENABLE, and RENEWAL studies]
Heart Failure
[Inhibition of renin-angiotensin-aldosterone system in heart failure, or from CONSENSUS to PARADIGM-HF].
Heart Failure
[Neprilysin inhibition and chronic kidney disease].
Heart Failure
[New medical therapies for the treatment of systolic heart failure]
Heart Failure
[New therapeutic era in heart failure with reduced ejection fraction: Which population of French patients is concerned?]
Heart Failure
[Study PARADIGM-HF - a paradigm shift in the treatment of chronic heart failure].
Heart Failure
[The effect of angiotensin receptors and neprilysin inhibitors on myocardial remodeling in patients with chronic heart failure and atrial fibrillation].
Heart Failure
[The relationship between natriuretic peptides and neprilysin pathways: the clinical simplification against the complexity of biological systems].
Heart Failure
[Update on heart failure].
Heart Failure
[«?ARNI?» (Angiotensin Receptor-Neprilysin Inhibitor): when, for whom and how?]
Heart Failure, Diastolic
Key advances in clinical cardiology.
Heart Failure, Systolic
A new class of drugs for systolic heart failure: The PARADIGM-HF study.
Heart Failure, Systolic
Beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID(2) ): an evidence-based mnemonic for the treatment of systolic heart failure.
Heart Failure, Systolic
Combined Inhibition of the Renin-Angiotensin System and Neprilysin Positively Influences Complex Mitochondrial Adaptations in Progressive Experimental Heart Failure.
Heart Failure, Systolic
Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice.
Heart Failure, Systolic
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
Heart Failure, Systolic
Dual Angiotensin Receptor and Neprilysin Inhibition in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
Heart Failure, Systolic
Morbidity and mortality in systolic heart failure also associated with raised serum neprilysin levels.
Heart Failure, Systolic
Morbidity and mortality in systolic heart failure also associated with raised serum neprilysin levels. Reply.
Heart Failure, Systolic
Update in recent clinical trials in heart failure.
Hematologic Neoplasms
Comparison of the expression of terminal deoxynucleotidyl transferase and common acute lymphoblastic leukemia antigen in selected hematologic malignancies.
Hematologic Neoplasms
Leukemia-associated antigens in ALL.
Hepatoblastoma
Expression of cell adhesion molecules and common acute lymphoblastic leukaemia antigen in hepatoblastoma.
Hepatomegaly
Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Herpes Simplex
Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo.
Herpes Simplex
Peptidomimetic design.
Hydronephrosis
Circulating adhesion molecules and neutral endopeptidase enzymuria in patients with urolithiasis and hydronephrosis.
Hyperaldosteronism
Renal kininases in primary aldosteronism.
Hyperaldosteronism
Significance of renal kininases in patients with primary aldosteronism.
Hyperalgesia
Inhibition of osteosarcoma-induced thermal hyperalgesia in mice by the orally active dual enkephalinase inhibitor PL37. Potentiation by gabapentin.
Hyperalgesia
Methylprednisolone prevents nerve injury-induced hyperalgesia in neprilysin knockout mice.
Hyperalgesia
Neutral endopeptidase knockout induces hyperalgesia in a model of visceral pain, an effect related to bradykinin and nitric oxide.
Hyperalgesia
The pro-nociceptive effects of remifentanil or surgical injury in mice are associated with a decrease in delta-opioid receptor mRNA levels: Prevention of the nociceptive response by on-site delivery of enkephalins.
Hypercalcemia
Severe Hypercalcemia in a Child With Acute Lymphoblastic Leukemia Relapse: Successful Management With Combination of Calcitonin and Bisphosphonate.
Hypercholesterolemia
Decrease in enkephalinase A number in kidney membranes from hypercholesterolemic and hypertensive rats.
Hyperglycemia
Effect of hyperglycemia and rosiglitazone on renal and urinary neprilysin in db/db diabetic mice.
Hyperkalemia
Hyperkalemia in heart failure: current treatment and new therapeutic perspectives.
Hyperkalemia
Management of Heart Failure Patient with CKD.
Hyperkalemia
Moderate potassium lowering effect of exogenous atrial natriuretic peptide in patients with acute heart failure.
Hyperkalemia
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
Hypersensitivity, Immediate
Inhibition of neutral endopeptidase augments anaphylactic constriction of guinea pig tracheal smooth muscle.
Hypertension
A comparison of the hypotensive effects of Met-enkephalin in normotensive and spontaneously hypertensive rats.
Hypertension
Adults with Down syndrome challenge another paradigm: When aging no longer entails arterial hypertension.
Hypertension
AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
Hypertension
An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension.
Hypertension
Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias.
Hypertension
Angiotensin-converting enzyme as a potential target for treatment of Alzheimer's disease: inhibition or activation?
Hypertension
Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans.
Hypertension
Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826. An orally active neutral metalloendopeptidase inhibitor.
Hypertension
Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: implications for novel therapeutic strategies.
Hypertension
Bradykinin and matrix metalloproteinases are involved the structural alterations of rat small resistance arteries with inhibition of ACE and NEP.
Hypertension
Cardiovascular effects of natriuretic peptides and their interrelation with endothelin-1.
Hypertension
Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
Hypertension
Chronic endopeptidase inhibition in DOCA-salt hypertension: mechanism of cardiovascular protection.
Hypertension
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor I: assay in plasma of human volunteers by atmospheric-pressure ionisation mass-spectrometry following derivatisation with BF3-methanol.
Hypertension
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor II: assay in the plasma and urine of human volunteers by dissociation enhanced lanthanide fluorescence immunoassay (DELFIA).
Hypertension
Combinatorial inhibition of Angiotensin converting enzyme, Neutral endopeptidase and Aminopeptidase N by N-methylated peptides alleviates blood pressure and fibrosis in rat model of dexamethasone-induced hypertension.
Hypertension
Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
Hypertension
Combined neutral endopeptidase inhibitors.
Hypertension
Computer modeling and nanosecond simulation of the enzyme-substrate complex of the common lymphoblastic leukemia antigen (neprilysin) indicates shared residues at the primary specificity pocket (S1') with matrix metalloproteases.
Hypertension
Current role of neprilysin inhibitors in hypertension and heart failure.
Hypertension
Decrease in enkephalinase A number in kidney membranes from hypercholesterolemic and hypertensive rats.
Hypertension
Decreased Neprilysin and Pulmonary Vascular Remodeling in Chronic Obstructive Pulmonary Disease.
Hypertension
Design and synthesis of an orally active macrocyclic neutral endopeptidase 24.11 inhibitor.
Hypertension
Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor.
Hypertension
Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
Hypertension
Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.
Hypertension
Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension.
Hypertension
Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.
Hypertension
Dual-Acting Angiotensin Receptor-Neprilysin Inhibition.
Hypertension
Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
Hypertension
Effects of a neutral endopeptidase inhibitor, BP102, on the development of deoxycorticosterone acetate-salt hypertension in kininogen-deficient Brown Norway Katholiek rats.
Hypertension
Effects of acute and chronic blockade of neutral endopeptidase with Sch 34826 on NaCl-sensitive hypertension in spontaneously hypertensive rats.
Hypertension
Effects of chronic neutral endopeptidase inhibition in rats with cyclosporine-induced hypertension.
Hypertension
Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
Hypertension
Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat.
Hypertension
Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid-? (A?) Plaque Load and A?-Synthesizing and A?-Degrading Enzymes in Frontal Cortex.
Hypertension
Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat.
Hypertension
Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Hypertension
Effects of omapatrilat on blood pressure and renal injury in L-NAME and L-NAME plus DOCA-treated rats.
Hypertension
Effects of omapatrilat on hemodynamics and safety in patients with heart failure.
Hypertension
Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension.
Hypertension
Effects of SA7060, a novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, on deoxycorticosterone acetate-salt-induced hypertension in rats.
Hypertension
Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.
Hypertension
Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study.
Hypertension
Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy.
Hypertension
Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (?65 Years) With Systolic Hypertension.
Hypertension
Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study.
Hypertension
Endopeptidase inhibition in angiotensin-induced hypertension. Effect of SCH 39370 in sheep.
Hypertension
Endopeptidase-24.11 and its inhibitors: potential therapeutic agents for edematous disorders and hypertension.
Hypertension
Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease.
Hypertension
First-in-Class Angiotensin Receptor Neprilysin Inhibitor in Heart Failure.
Hypertension
Hemodynamic and humoral effects of chronic treatment with the neutral endopeptidase inhibitor SCH 42495 in spontaneously hypertensive rats.
Hypertension
Hydrolysis of alpha-human atrial natriuretic peptide in vitro by human kidney membranes and purified endopeptidase-24.11. Evidence for a novel cleavage site.
Hypertension
Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension.
Hypertension
Hypertension up to date: SPRINT to SPYRAL.
Hypertension
Hypertension: LCZ696, a novel dual inhibitor of neprilysin and the angiotensin II receptor, shows promise in phase II trial.
Hypertension
Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension.
Hypertension
Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid.
Hypertension
Improved Insulin Sensitivity with Angiotensin Receptor Neprilysin Inhibition in Individuals with Obesity and Hypertension.
Hypertension
In silico based investigation of dynamic variations in neprilysin (NEP and NEP2) proteins for extracting the point of specificity.
Hypertension
Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Hypertension
Key advances in clinical cardiology.
Hypertension
Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
Hypertension
Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
Hypertension
Natriuretic peptides and neprilysin inhibition in hypertension and hypertensive organ damage.
Hypertension
Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial.
Hypertension
New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11.
Hypertension
New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension.
Hypertension
New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
Hypertension
New thiol inhibitors of neutral endopeptidase EC 3.4.24.11: synthesis and enzyme active-site recognition.
Hypertension
Omapatrilat. Bristol-Myers Squibb.
Hypertension
Omapatrilat: penetration across the blood-brain barrier and effects on ischaemic stroke in rats.
Hypertension
Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
Hypertension
Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240.
Hypertension
Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats.
Hypertension
Peptide metabolism and the control of body fluid homeostasis.
Hypertension
Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol.
Hypertension
Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
Hypertension
Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).
Hypertension
Potentiation of brain natriuretic peptides by SQ 28,603, an inhibitor of neutral endopeptidase 3.4.24.11, in monkeys and rats.
Hypertension
Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study.
Hypertension
Reciprocal regulation of angiotensin converting enzyme and neutral endopeptidase in rats with experimental hypertension.
Hypertension
Renal and antihypertensive effects of neutral endopeptidase inhibition in transgenic rats with an extra renin gene.
Hypertension
Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials.
Hypertension
Role of neutral endopeptidase and angiotensin-converting enzyme in deoxycorticosterone acetate-salt hypertension.
Hypertension
Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts.
Hypertension
Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
Hypertension
Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.
Hypertension
Sampatrilat Shire.
Hypertension
Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease.
Hypertension
Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
Hypertension
Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin Inhibitors.
Hypertension
Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.
Hypertension
The atriopeptidase inhibitor UK 69,578 increases atrial natriuretic factor and causes a natriuresis in normal humans.
Hypertension
The natriuretic peptides in hypertension.
Hypertension
The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
Hypertension
Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II-Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension.
Hypertension
Vasopeptidase inhibition for blood pressure control: emerging experience.
Hypertension
Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertension.
Hypertension
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
Hypertension
Vasopeptidase inhibitors: will they have a role in clinical practice?
Hypertension
[Changing the paradigm: valsartan-inhibitor of neprilysin, a new dual-acting drug for arterial hypertension and heart failure].
Hypertension
[Dual inhibition of converting enzyme and neutral endopeptidase: a research new way in the field of hypertension]
Hypertension
[Membrane metalloendopeptidase (CD10/CALLA): distribution, physiologic and pathophysiologic functions and its inhibitors]
Hypertension
[OCTAVE and OPERA: discordance in hypertension therapy?]
Hypertension, Portal
Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats.
Hypertension, Pulmonary
Augmentation of the effects of vasoactive intestinal peptide aerosol on pulmonary hypertension via co-application of a neutral endopeptidase 24.11 inhibitor.
Hypertension, Pulmonary
Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure.
Hypertension, Pulmonary
Effects of SCH 34826, a neutral endopeptidase inhibitor, on hypoxic pulmonary vascular remodelling.
Hypertension, Pulmonary
Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease.
Hypertension, Pulmonary
Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia.
Hypertension, Pulmonary
Neutral endopeptidase (NEP) inhibition in rats with established pulmonary hypertension secondary to chronic hypoxia.
Hypertension, Pulmonary
Neutral endopeptidase 24.11 inhibition reduces pulmonary vascular remodeling in rats exposed to chronic hypoxia.
Hypertension, Pulmonary
Neutral endopeptidase inhibition attenuates development of hypoxic pulmonary hypertension in rats.
Hypertension, Pulmonary
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.
Hypertension, Pulmonary
Role of endogenous ANP in sodium excretion in rats with experimental pulmonary hypertension.
Hypertension, Pulmonary
Soluble neprilysin does not correlate with prognosis in pulmonary hypertension.
Hypertension, Pulmonary
The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature.
Hypertension, Pulmonary
Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
Hypertension, Renovascular
Effects of Angiotensin II Type 1A Receptor on ACE2, Neprilysin and KIM-1 in Two Kidney One Clip (2K1C) Model of Renovascular Hypertension.
Hypertrophy, Left Ventricular
Chronic inhibition of neutral endopeptidase reduces left ventricular hypertrophy without changing blood pressure in spontaneously hypertensive rats.
Hypertrophy, Left Ventricular
Effects of SCH 42495, a neutral endopeptidase inhibitor, on cardiac function and mass in rats after repeated hyperbaric exposures.
Hypertrophy, Left Ventricular
The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats.
Hypertrophy, Right Ventricular
Neutral endopeptidase 24.11 inhibition reduces pulmonary vascular remodeling in rats exposed to chronic hypoxia.
Hypotension
Cardiovascular effects of nociceptin in unanesthetized mice.
Hypotension
Effect of pharmacological manipulation of endogenous atriopeptin activity on renal function.
Hypotension
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).
Hypotension
Limitations of Sacubitril/Valsartan in the Management of Heart Failure.
Hypotension
Novel doses of sacubitril/valsartan in patients unable to tolerate traditional therapy: Effects on N-terminal pro B-type natriuretic peptide levels.
Hypotension
Overexpression of kidney neutral endopeptidase (EC 3.4.24.11) and renal function in experimental cirrhosis.
Infant, Newborn, Diseases
Neonatal disease in neutral endopeptidase alloimmunization: lessons for immunological monitoring.
Infections
A New Natural Host of Lisianthus necrosis virus in Taiwan
Infections
A New Natural Host of Lisianthus necrosis virus in Taiwan.
Infections
Airway hyper-responsiveness to neurokinin A and bradykinin following Mycoplasma pneumoniae infection associated with reduced epithelial neutral endopeptidase.
Infections
First Report of Carnation mottle virus in Calla lily (Zantedeschia spp.).
Infections
First report of Carnation mottle virus in Calla lily (Zantedeschia spp.).
Infections
First Report of Tomato spotted wilt virus and Impatiens necrotic spot virus in Slovenia.
Infections
First report of Tomato spotted wilt virus and Impatiens necrotic spot virus in Slovenia.
Infections
Genetic transformation of Ornithogalum via particle bombardment and generation of Pectobacterium carotovorum-resistant plants.
Infections
HIV-1 Tat inhibits neprilysin and elevates amyloid beta.
Infections
Human cytomegalovirus infection downregulates expression of the cellular aminopeptidases CD10 and CD13.
Infections
Identification of a Potyvirus Causing Latent Infection in Calla Lilies.
Infections
Identification of Turnip mosaic virus Isolates Causing Yellow Stripe and Spot on Calla Lily
Infections
Identification of Turnip mosaic virus Isolates Causing Yellow Stripe and Spot on Calla Lily.
Infections
Influenza infection causes airway hyperresponsiveness by decreasing enkephalinase.
Infections
Proteomic Analysis of Urine from California Sea Lions ( Zalophus californianus): A Resource for Urinary Biomarker Discovery.
Infections
The etiology of congenital nephrotic syndrome: current status and challenges.
Infections
The ultrastructure and permeability of tracheobronchial blood vessels in health and disease.
Infertility
Peptides in Seminal Fluid and Their Role in Infertility: A Potential Role for Opiorphin Inhibition of Neutral Endopeptidase Activity as a Clinically Relevant Modulator of Sperm Motility: A Review.
Inflammatory Bowel Diseases
Ability of human colonic epithelium to express the 4F2 antigen, the common acute lymphoblastic leukemia antigen, and the transferrin receptor. Studies in inflammatory bowel disease and after in vitro exposure to different stimuli.
Inflammatory Bowel Diseases
Anti-Inflammatory Effect of Homo- and Heterodimers of Natural Enkephalinase Inhibitors in Experimental Colitis in Mice.
Inflammatory Bowel Diseases
Increase in substance P precursor mRNA in noninflamed small-bowel sections in patients with Crohn's disease.
Influenza, Human
Influenza infection causes airway hyperresponsiveness by decreasing enkephalinase.
Insulin Resistance
Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat.
Insulin Resistance
Brain-Wide Insulin Resistance, Tau Phosphorylation Changes, and Hippocampal Neprilysin and Amyloid-? Alterations in a Monkey Model of Type 1 Diabetes.
Insulin Resistance
Effect of pioglitazone on altered expression of A? metabolism-associated molecules in the brain of fructose-drinking rats, a rodent model of insulin resistance.
Insulin Resistance
Effects of dual angiotensin-converting enzyme and neutral endopeptidase 24-11 chronic inhibition by mixanpril on insulin sensitivity in lean and obese Zucker rats.
Insulin Resistance
Improved Insulin Sensitivity with Angiotensin Receptor Neprilysin Inhibition in Individuals with Obesity and Hypertension.
Insulin Resistance
Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia.
Insulin Resistance
The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients.
Iron Deficiencies
New drugs: big changes in conservative heart failure therapy?
Iron Deficiencies
[Heart failure and iron deficiency].
Keloid
Multi-Antigen Imaging Reveals Inflammatory DC, ADAM17 and Neprilysin as Effectors in Keloid Formation.
Keratoconus
Immunohistochemical Expression of Fas Ligand (FasL) and Neprilysin (Neutral endopeptidase/CD10) in Keratoconus.
Kidney Diseases
Circulating Neprilysin Level Predicts the Risk of Cardiovascular Events in Hemodialysis Patients.
Kidney Diseases
Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin Inhibitors.
Kidney Diseases
Urinary neprilysin for early detection of acute kidney injury after cardiac surgery: A prospective observational study.
Kidney Failure, Chronic
Endothelin-converting enzyme-1 inhibition and renoprotection in end-stage renal disease.
Kidney Failure, Chronic
Enhanced natriuretic response to neutral endopeptidase inhibition in patients with moderate chronic renal failure.
Kidney Failure, Chronic
Inhibition of neutral endopeptidase stimulates renal sodium excretion in patients with chronic renal failure.
Kidney Failure, Chronic
Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure.
Kidney Failure, Chronic
Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage.
Kidney Failure, Chronic
[Neprilysin inhibition and chronic kidney disease].
Kidney Neoplasms
Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent.
Latent Infection
Identification of a Potyvirus Causing Latent Infection in Calla Lilies.
Latent Infection
Identification of a potyvirus causing latent infection in calla lilies.
Leiomyoma
Differential expression of mRNAs for endothelin-related proteins in human endometrium, myometrium and leiomyoma.
Leptospirosis
Proteomic Analysis of Urine from California Sea Lions ( Zalophus californianus): A Resource for Urinary Biomarker Discovery.
Leukemia
A new tumor marker for bladder cancer.
Leukemia
A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
Leukemia
Acute leukemia with chromosome translocation (4;11): 7 new patients and analysis of 71 cases.
Leukemia
Acute leukemias with both myeloid and lymphoid surface markers. Cytoplasmic alpha-1-anti-chymotrypsin and alpha-1-anti-trypsin as possible indicators of early granulocytic differentiation.
Leukemia
Application of series of monoclonal antibodies against human white cell differentiation antigens and the common ALL antigen in the characterization of leukemia cells.
Leukemia
CALLA negative precursor B lymphoblastic leukemia with MLL gene translocation and an unusual FISH signal pattern.
Leukemia
CD10 and CD44 genes of leukemic cells and malignant cell lines show no evidence of transformation-related alterations.
Leukemia
CD10 expression is useful in the diagnosis of follicular carcinoma and follicular variant of papillary thyroid carcinoma.
Leukemia
Classification of human leukemia by membrane antigen analysis with xenoantisera.
Leukemia
Clinical and laboratory characteristics of acute leukemia with the 4;11 translocation.
Leukemia
Clinical significance of HLA-DR+, CD19+, CD10+ immature B-cell phenotype and CD34+ cell detection in bone marrow lymphocytes from children affected with immune thrombocytopenic purpura.
Leukemia
Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ("enkephalinase"): direct evidence by cDNA transfection analysis.
Leukemia
Common acute lymphoblastic leukemia antigen expressed on leukemia and melanoma cell lines has neutral endopeptidase activity.
Leukemia
Comparative levels of CALLA/neutral endopeptidase on normal granulocytes, leukemic cells, and transfected COS-1 cells.
Leukemia
Comparison of the expression of terminal deoxynucleotidyl transferase and common acute lymphoblastic leukemia antigen in selected hematologic malignancies.
Leukemia
Cytological and immunological study of 139 patients with acute leukemia.
Leukemia
Detection of central nervous system relapse in acute leukemia by multiparameter flow cytometry of DNA, RNA, and CALLA.
Leukemia
Detection of the common acute lymphoblastic leukemia antigen in the serum of leukemia patients.
Leukemia
Distribution and modulation of a human leukemia-associated antigen (CALLA).
Leukemia
Down's syndrome and acute leukemia in children: an analysis of phenotype by use of monoclonal antibodies and electron microscopic platelet peroxidase reaction.
Leukemia
Expression of cALLa/NEP on gliomas: a possible marker of malignancy.
Leukemia
Human glioma cell lines expressing the common acute lymphoblastic leukemia antigen (cALLa) have neutral endopeptidase activity.
Leukemia
Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.
Leukemia
Immunophenotype of leukemic blasts with small peroxidase-positive granules detected by electron microscopy.
Leukemia
Immunophenotypic, cytogenetic and molecular investigations in two cases of CALLA positive acute myeloid leukemia.
Leukemia
In vitro and in vivo cytotoxic activity of anti-human leukemia monoclonal antibodies SN5c and SN6 daunorubicin conjugates.
Leukemia
Induction of apoptosis and CD10/neutral endopeptidase expression by jaspamide in HL-60 line cells.
Leukemia
Leukemic myeloblasts expressing lymphoid markers.
Leukemia
Long-term culture of infant leukemia cells: dependence upon stromal cells from the bone marrow and bilineage differentiation.
Leukemia
Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein.
Leukemia
Monoclonal antibodies to CALLA do not alter polymorphonuclear functions.
Leukemia
Monocyte markers and the common acute lymphoblastic leukemia antigen on chronic lymphocytic leukemia cells.
Leukemia
Occurrence of the common acute lymphoblastic leukemia antigen on blast cells of a patient with chronic myelomonocytic leukemia in non-lymphoid blastic phase.
Leukemia
Persistence of bone marrow lymphocytosis after induction treatment in common acute lymphoblastic leukemia. Marker analysis and significance.
Leukemia
Phorbol ester-mediated regulation of CD10/neutral endopeptidase transcripts in acute lymphoblastic leukemias.
Leukemia
Photoradiation methods for purging autologous bone marrow grafts.
Leukemia
Pseudomonas diarrhea in a child suffering from acute lymphatic leukemia.
Leukemia
Rabbit antiserum against a non-T, non-B leukemia cell line that carries the Ph1 chromosome (NALM-1): antibody specific to a non-T, non-B acute lymphoblastic leukemia antigen.
Leukemia
Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen.
Leukemia
Shifts in blast cell phenotype and karyotype at relapse of childhood lymphoblastic leukemia.
Leukemia
Terminal deoxynucleotidyl transferase in acute leukemias by direct immunofluorescence.
Leukemia
Tonsillar mapping of determinants found on normal lymphoreticular (T,B,K, immature and macrophage) and myeloblastic leukemia cells.
Leukemia
Unique epitopes of common acute lymphoblastic leukemia antigen detected by new monoclonal antibodies.
Leukemia
[Acute mixed-cell human leukemia]
Leukemia
[Immunologic and enzymatic markers of acute infantile lymphoblastic leukemias]
Leukemia
[Preparation and cytotoxicity of McAb-HSA-MTX conjugates]
Leukemia, Lymphocytic, Chronic, B-Cell
B-cell neoplasms of the lymphocytic, lymphoplasmacytoid, and plasma cell types: immunohistologic analysis and clinical correlation.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.
Leukemia, Lymphocytic, Chronic, B-Cell
Monocyte markers and the common acute lymphoblastic leukemia antigen on chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Pre-T chronic lymphocytic leukemia with common acute lymphoblastic leukemia antigen. A new immunologic variant.
Leukemia, Lymphocytic, Chronic, B-Cell
[The presence of CALLA (common acute lymphoblastic leukemia antigens) and B-cell differentiation antigens in lymphocytic lymphoma]
Leukemia, Lymphoid
Difference between monoclonal antibodies against the common acute leukemia antigen from two different hybridomas.
Leukemia, Monocytic, Acute
Leukemic myeloblasts expressing lymphoid markers.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Comparison of the expression of terminal deoxynucleotidyl transferase and common acute lymphoblastic leukemia antigen in selected hematologic malignancies.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Human leukemia-associated antigen: relation to a family of surface glycoproteins.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia-associated antigens in ALL.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Separation of lymphoid and myeloid blasts in the mixed blast crisis of chronic myelogenous leukemia: no evidence for Ig gene rearrangement in CALLA-positive blasts.
Leukemia, Myeloid, Acute
Biologic and cytogenetic characteristics of leukemia in infants.
Leukemia, Myeloid, Acute
Detection of the common acute lymphoblastic leukemia antigen in the serum of leukemia patients.
Leukemia, Myeloid, Acute
Identification of several cell surface proteins of non-T, non-B acute lymphoblastic leukemia by using monoclonal antibodies.
Leukemia, Myeloid, Acute
Immunophenotypic, cytogenetic and molecular investigations in two cases of CALLA positive acute myeloid leukemia.
Leukemia, Myeloid, Acute
Leukemia-associated antigens in ALL.
Leukemia, Myeloid, Acute
Secondary T-cell lymphoproliferation after marrow transplantation.
Leukemia, Myeloid, Acute
Shifts in blast cell phenotype and karyotype at relapse of childhood lymphoblastic leukemia.
Leukemia, Myelomonocytic, Chronic
Occurrence of the common acute lymphoblastic leukemia antigen on blast cells of a patient with chronic myelomonocytic leukemia in non-lymphoid blastic phase.
Leukemia, Plasma Cell
Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.
Leukemia, Plasma Cell
Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen.
Leukemia, Promyelocytic, Acute
Photoradiation methods for purging autologous bone marrow grafts.
Lewy Body Disease
Neprilysin Activity in Cerebrospinal Fluid is Associated with Dementia and Amyloid-?42 Levels in Lewy Body Disease.
Lipoma
CD10 (neprilysin) expression: a potential adjunct in the distinction of hibernoma from morphologic mimics.
Liver Cirrhosis, Biliary
[Activity of neutral endopeptidase in serum of patients with primary biliary cirrhosis]
Liver Diseases
Neutral endopeptidase activity is not elevated in serum in children with cholestatic liver disease: a unique role of aminopeptidase-m in sequential hydrolysis of peptides.
Lung Diseases
Limitations of Sacubitril/Valsartan in the Management of Heart Failure.
Lung Injury
A possible involvement of oxidative lung injury in endotoxin-induced bronchial hyperresponsiveness to substance P in guinea pigs.
Lung Injury
Alleviation of wood smoke-induced lung injury by tachykinin receptor antagonist and hydroxyl radical scavenger in guinea pigs.
Lung Injury
Characterization of a soluble form of neutral endopeptidase-24.11 (EC 3.4.24.11) in human serum: enhancement of its activity in serum of underground miners exposed to coal dust particles.
Lung Injury
Neutral endopeptidase determines the severity of pancreatitis-associated lung injury.
Lung Injury
Recombinant human neutral endopeptidase ameliorates pancreatic elastase-induced lung injury.
Lung Neoplasms
Effects of recombinant neutral endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo.
Lung Neoplasms
Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model - role of tumor stroma cells.
Lung Neoplasms
Inactivation of neutral endopeptidase in lung cancer.
Lung Neoplasms
Low neutral endopeptidase levels in bronchoalveolar lavage fluid of lung cancer patients.
Lung Neoplasms
Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung cancer.
Lung Neoplasms
Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux.
Lupus Erythematosus, Systemic
The etiology of congenital nephrotic syndrome: current status and challenges.
Lymphadenopathy
Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Lymphocytosis
Persistence of bone marrow lymphocytosis after induction treatment in common acute lymphoblastic leukemia. Marker analysis and significance.
Lymphoma
A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
Lymphoma
A variant Burkitt-type translocation (2p-;8q+) in a patient with diffuse large cell lymphoma.
Lymphoma
Aggressive Diffuse Lymphoma Coexpressing NRAS p21 and C-erbB-2 (neu) Oncogene Products, and CALL A (CD 10).
Lymphoma
An ultrastructural morphometric and immunophenotypic evaluation of Burkitt's and Burkitt's-like lymphomas.
Lymphoma
Anatomical distribution of call antigen expressing cells in normal lymphatic tissue and in lymphomas.
Lymphoma
CD10 and CD44 genes of leukemic cells and malignant cell lines show no evidence of transformation-related alterations.
Lymphoma
CD10 expression is useful in the diagnosis of follicular carcinoma and follicular variant of papillary thyroid carcinoma.
Lymphoma
CD10 is expressed in cutaneous clear cell lesions of different histogenesis.
Lymphoma
Clinical significance of HLA-DR+, CD19+, CD10+ immature B-cell phenotype and CD34+ cell detection in bone marrow lymphocytes from children affected with immune thrombocytopenic purpura.
Lymphoma
Common acute lymphoblastic leukemia-associated antigen (CALLA)-positive B cell lymphoma.
Lymphoma
Detection of central nervous system relapse in acute leukemia by multiparameter flow cytometry of DNA, RNA, and CALLA.
Lymphoma
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.
Lymphoma
Follicular large cell lymphoma. An immunophenotype study.
Lymphoma
Immunophenotypic characterization of follicle-center-cell-derived non-Hodgkin's lymphomas.
Lymphoma
Leukemia derived from intermediately differentiated lymphocytic lymphoma.
Lymphoma
Lymphocyte malignancy and chromosome 14: structural aberrations involving band q11.
Lymphoma
Reactivity of Leu 1 and T101 monoclonal antibodies with B cell lymphomas (correlations with other immunological markers).
Lymphoma
[Immunologic phenotypes of germinal center cell tumors]
Lymphoma, B-Cell
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.
Lymphoma, B-Cell
Overexpression of microRNA-130a predicts adverse prognosis of primary gastrointestinal diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Photoradiation methods for purging autologous bone marrow grafts.
Lymphoma, Follicular
Common acute lymphoblastic leukemia-associated antigen (CALLA)-positive B cell lymphoma.
Lymphoma, Follicular
Follicular large cell lymphoma. An immunophenotype study.
Lymphoma, Follicular
Localization and imaging with radioiodine-labeled monoclonal antibodies in a xenogeneic tumor model for human B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Follicular large cell lymphoma. An immunophenotype study.
Lymphoma, Non-Hodgkin
Common acute lymphoblastic leukemia-associated antigen (CALLA)-positive B cell lymphoma.
Lymphoma, Non-Hodgkin
Thiorphan stimulates clonal growth of GM-CFU in short-term cultures of bone marrow from a healthy donor and from patients with non-Hodgkin lymphoma.
Lymphoma, T-Cell
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.
Lymphoma, T-Cell, Peripheral
Lymphocyte malignancy and chromosome 14: structural aberrations involving band q11.
Macular Degeneration
Long-term neprilysin inhibition - implications for ARNIs.
Melanoma
Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma.
Melanoma
Common acute lymphoblastic leukemia antigen expressed on leukemia and melanoma cell lines has neutral endopeptidase activity.
Melanoma
Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma.
Melanoma
Degradation of alpha-melanocyte stimulating hormone (alpha-MSH) by CALLA/endopeptidase 24.11 expressed by human melanoma cells in culture.
Melanoma
Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin.
Melanoma
Expression of common acute lymphoblastic leukemia antigen (CALLA) on human malignant melanoma cell lines.
Melanoma
Expression of IL-2 receptors in human melanoma cells.
Melanoma
Human glioma cell lines expressing the common acute lymphoblastic leukemia antigen (cALLa) have neutral endopeptidase activity.
Melanoma
[Expression of neutral endopeptidase and motility-related protein-1 in cutaneous malignant melanoma]
Memory Disorders
?-Hydroxybutyrate (Xyrem) ameliorates clinical symptoms and neuropathology in a mouse model of Alzheimer's disease.
Memory Disorders
Drosophila neprilysin 1 rescues memory deficits caused by amyloid-? peptide.
Memory Disorders
Drosophila Neprilysins Are Involved in Middle-Term and Long-Term Memory.
Memory Disorders
Neuronal neprilysin overexpression is associated with attenuation of Abeta-related spatial memory deficit.
Memory Disorders
Peripheral delivery of a CNS targeted, metalo-protease reduces a? toxicity in a mouse model of Alzheimer's disease.
Menorrhagia
Endothelin and neutral endopeptidase in the endometrium of women with menorrhagia.
Mercury Poisoning
The etiology of congenital nephrotic syndrome: current status and challenges.
Metabolic Syndrome
Neprilysin, obesity and the metabolic syndrome.
Metabolic Syndrome
Neutral endopeptidase inhibitor versus angiotensin converting enzyme inhibitor in a rat model of the metabolic syndrome.
Metabolic Syndrome
Nonclassical Axis of the Renin-Angiotensin System and Neprilysin: Key Mediators That Underlie the Cardioprotective Effect of PPAR-Alpha Activation during Myocardial Ischemia in a Metabolic Syndrome Model.
Metabolic Syndrome
Vascular and neural dysfunctions in obese Zucker rats: effect of AVE7688.
Microphthalmos
Neprilysin, a novel target for ultraviolet B regulation of melanogenesis via melanocortins.
Migraine Disorders
Hypernociceptive syndromes and pharmacological inhibition of endogenous opioid degradation.
Miosis
Administration of recombinant enkephalinase (neutral endopeptidase) prevents capsaicin-induced miosis in the rabbit eye in vivo.
Miosis
Recombinant enkephalinase effectively inhibits substance P-induced miosis in the rabbit eye cup model.
Mitral Valve Insufficiency
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation: The PRIME Study.
Mitral Valve Insufficiency
Effect of Neprilysin Inhibition for Ischemic Mitral Regurgitation after Myocardial Injury.
Monoclonal Gammopathy of Undetermined Significance
Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells.
Multiple Myeloma
B-cell neoplasms of the lymphocytic, lymphoplasmacytoid, and plasma cell types: immunohistologic analysis and clinical correlation.
Multiple Myeloma
Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.
Multiple Myeloma
Multiple myeloma: the relationship between CALLA (CD10) positive lymphocytes in the peripheral blood and light chain isotype suppression.
Multiple Myeloma
Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells.
Multiple Sclerosis
Increased expression of neutral endopeptidase (NEP) and aminopeptidase N (APN) on peripheral blood mononuclear cells in patients with multiple sclerosis.
Muscle Weakness
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.
Muscular Diseases
Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusion-body myopathy muscle.
Mycoplasma Infections
Airway hyper-responsiveness to neurokinin A and bradykinin following Mycoplasma pneumoniae infection associated with reduced epithelial neutral endopeptidase.
Mycosis Fungoides
Mycosis fungoides of the larynx: case report and review of the literature.
Myocardial Infarction
Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction.
Myocardial Infarction
Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
Myocardial Infarction
Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
Myocardial Infarction
AT1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in rats.
Myocardial Infarction
Bradykinin metabolism in rat hearts with left-ventricular hypertrophy following myocardial infarction.
Myocardial Infarction
Correction to: Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction.
Myocardial Infarction
Discrepancy between plasma and lung angiotensin-converting enzyme activity in experimental congestive heart failure. A novel aspect of endothelium dysfunction.
Myocardial Infarction
Effect of chronic neutral endopeptidase inhibition on cardiac hypertrophy after experimental myocardial infarction.
Myocardial Infarction
Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction.
Myocardial Infarction
Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction.
Myocardial Infarction
Effect on prolonged inhibition of neutral endopeptidase on cardiac hypertrophy in rats with myocardial infarction.
Myocardial Infarction
Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
Myocardial Infarction
Effects of Angiotensin Receptor Neprilysin Inhibitors on Inducibility of Ventricular Arrhythmias in Rats with Ischemic Cardiomyopathy.
Myocardial Infarction
Effects of captopril and omapatrilat on early post-myocardial infarction survival and cardiac hemodynamics in rats: interaction with cardiac cytokine expression.
Myocardial Infarction
Effects of neutral endopeptidase 24.11 inhibition on myocardial infarct size and ischemic preconditioning in rabbits.
Myocardial Infarction
Ex vivo effects of an Oenothera paradoxa extract on the reactive oxygen species generation and neutral endopeptidase activity in neutrophils from patients after acute myocardial infarction.
Myocardial Infarction
Heart failure augments the cardiovascular and renal effects of neutral endopeptidase inhibition in rats.
Myocardial Infarction
Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction.
Myocardial Infarction
Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
Myocardial Infarction
Inhibition of human neutrophils NEP activity, CD11b/CD18 expression and elastase release by 3,4-dihydroxyphenylethanol-elenolic acid dialdehyde, oleacein.
Myocardial Infarction
Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Myocardial Infarction
Intravenous morphine reduces plasma endothelin 1 concentration through activation of neutral endopeptidase 24.11 in patients with myocardial infarction.
Myocardial Infarction
Natriuretic peptide-potentiating actions of neutral endopeptidase inhibition in rats with experimental heart failure.
Myocardial Infarction
Neprilysin inhibitors and chest pain perception in acute myocardial infarction.
Myocardial Infarction
Neprilysin levels at the acute phase of ST-elevation myocardial infarction.
Myocardial Infarction
Omapatrilat limits infarct size and lowers the threshold for induction of myocardial preconditioning through a bradykinin receptor-mediated mechanism.
Myocardial Infarction
Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling.
Myocardial Infarction
Renal denervation ameliorates post-infarction cardiac remodeling in rats through dual regulation of oxidative stress in the heart and brain.
Myocardial Infarction
Sacubitril and valsartan protect from experimental myocardial infarction by ameliorating oxidative damage in Wistar rats.
Myocardial Infarction
Serum neprilysin levels are associated with myocardial stunning after ST-elevation myocardial infarction.
Myocardial Infarction
The Rationale of Neprilysin Inhibition in Prevention of Myocardial Ischemia-Reperfusion Injury during ST-Elevation Myocardial Infarction.
Myocardial Ischemia
Nonclassical Axis of the Renin-Angiotensin System and Neprilysin: Key Mediators That Underlie the Cardioprotective Effect of PPAR-Alpha Activation during Myocardial Ischemia in a Metabolic Syndrome Model.
Myocardial Ischemia
Soluble neprilysin and long-term clinical outcomes in patients with coronary artery disease undergoing percutaneous coronary intervention: a retrospective cohort study.
Myocardial Stunning
Serum neprilysin levels are associated with myocardial stunning after ST-elevation myocardial infarction.
Myositis
Neprilysin participates in skeletal muscle regeneration and is accumulated in abnormal muscle fibres of inclusion body myositis.
Myositis, Inclusion Body
Neprilysin participates in skeletal muscle regeneration and is accumulated in abnormal muscle fibres of inclusion body myositis.
Nasal Obstruction
Role of neutral endopeptidase and kininase II on substance P-induced increase in nasal obstruction in patients with allergic rhinitis.
Neoplasm Metastasis
Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma.
Neoplasm Metastasis
Ectopeptidases in tumour biology: a review.
Neoplasm Metastasis
Epigenetic suppression of neprilysin regulates breast cancer invasion.
Neoplasm Metastasis
Membrane Metalloendopeptidase (MME) Suppresses Metastasis of Esophageal Squamous Cell Carcinoma (ESCC) by Inhibiting FAK-RhoA Signaling Axis.
Neoplasm Metastasis
Neutral endopeptidase depletion decreases colon cancer cell proliferation and TGF-?1 synthesis in indirect co-cultures with normal colon fibroblasts.
Neoplasm Metastasis
Thalidomide combined with irradiation alters the activity of two proteases.
Neoplasms
"To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
Neoplasms
(99m)Tc-labeled gastrins of varying peptide chain length: Distinct impact of NEP/ACE-inhibition on stability and tumor uptake in mice.
Neoplasms
A Japanese Burkitt's lymphoma with t(2;8) and EBNA.
Neoplasms
A labeled neutral endopeptidase inhibitor as a potential tool for tumor diagnosis and prognosis.
Neoplasms
A monoclonal antibody to common acute lymphoblastic leukemia antigen (CALLA) and its expression on several human tumor cell lines.
Neoplasms
A new tumor marker for bladder cancer.
Neoplasms
A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
Neoplasms
Acute lymphoblastic leukemia presenting as nephromegaly in a child: A rare case report.
Neoplasms
Amide-to-triazole switch vs. in vivo NEP-inhibition approaches to promote radiopeptide targeting of GRPR-positive tumors.
Neoplasms
Anatomical distribution of call antigen expressing cells in normal lymphatic tissue and in lymphomas.
Neoplasms
Anti-progressive effect of neutral endopeptidase 24.11 (NEP/CD10) on cervical carcinoma in vitro and in vivo.
Neoplasms
Autoimmunoregulation: differential modulation of CD10/neutral endopeptidase 24.11 by tumor necrosis factor and neuropeptides.
Neoplasms
B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes.
Neoplasms
CD10 and CD44 genes of leukemic cells and malignant cell lines show no evidence of transformation-related alterations.
Neoplasms
CD10 immunoreactivity in sarcomatoid carcinomas: comparison with true sarcomas.
Neoplasms
Cell specific expression of CD10/neutral endopeptidase 24.11 gene in human prostatic tissue and cells.
Neoplasms
Changes in cell-surface peptidase activity in papillary renal cell carcinoma.
Neoplasms
Characterization of malignant and non-neoplastic cell phenotypes in highly malignant non-Hodgkin lymphomas.
Neoplasms
Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma.
Neoplasms
Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ("enkephalinase"): direct evidence by cDNA transfection analysis.
Neoplasms
Comparing Gly11/dAla11-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the 111In-SB3/111In-SB4 Radiotracer Pair.
Neoplasms
Comparison of the expression of terminal deoxynucleotidyl transferase and common acute lymphoblastic leukemia antigen in selected hematologic malignancies.
Neoplasms
Computer modeling and nanosecond simulation of the enzyme-substrate complex of the common lymphoblastic leukemia antigen (neprilysin) indicates shared residues at the primary specificity pocket (S1') with matrix metalloproteases.
Neoplasms
Concise Review: Neutral Endopeptidase (CD10): A Multifaceted Environment Actor in Stem Cells, Physiological Mechanisms, and Cancer.
Neoplasms
Concise Review: Neutral Endopeptidase (NEP/CD10): A Multifaceted Environment Actor in Stem Cells, Physiological Mechanisms and Cancer.
Neoplasms
Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma.
Neoplasms
Cytokines and glucocorticoids modulate human bronchial epithelial cell peptidases.
Neoplasms
Dendrobiumpolysaccharides attenuate cognitive impairment in senescence-accelerated mouse prone 8 mice via modulation of microglial activation.
Neoplasms
Differential diagnostic significance of epithelial and stromal CD10 expression in tumors of trichogenic origin.
Neoplasms
Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin.
Neoplasms
Ectoenzyme regulation by phenotypically distinct fibroblast sub-populations isolated from the human mammary gland.
Neoplasms
Ectopeptidases in tumour biology: a review.
Neoplasms
Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
Neoplasms
Enkephalinase activity in the intestinal epithelial cells of the fetus of 19 days and their immortalized and transformed counterparts the SLC-cell lines.
Neoplasms
Epigenetic suppression of neprilysin regulates breast cancer invasion.
Neoplasms
Epithelial-myoepithelial carcinoma of the minor salivary glands: immunohistochemical and morphological features.
Neoplasms
Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients.
Neoplasms
Expression and Regulatory Network Analysis of MiR-139-3p, a New Potential Serum Biomarker for Esophageal Squamous Cell Carcinoma Based on Bioinformatics Analysis.
Neoplasms
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.
Neoplasms
Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues.
Neoplasms
Expression of the common acute lymphoblastic leukemia antigen (CD10) in mesenchymal tumors.
Neoplasms
Future pharmacologic agents for treatment of heart failure in children.
Neoplasms
High concentration of neutral endopeptidase (enkephalinase E.C. 3.4.24.11) in a malignant tumor: rat hepatoma 3924A.
Neoplasms
Human leukemia-associated antigen: relation to a family of surface glycoproteins.
Neoplasms
Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model - role of tumor stroma cells.
Neoplasms
Icariside II, a novel phosphodiesterase-5 inhibitor, attenuates streptozotocin-induced cognitive deficits in rats.
Neoplasms
Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.
Neoplasms
Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid.
Neoplasms
Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [(111)In-DOTA]MG11-first estimates for clinical translation.
Neoplasms
In vitro and in vivo cytotoxic activity of anti-human leukemia monoclonal antibodies SN5c and SN6 daunorubicin conjugates.
Neoplasms
Increase of CALLA-positive stimulated lymphoid cells in transient erythroblastopenia of childhood.
Neoplasms
Induction of differentiation of African Burkitt's lymphoma cells by phorbol ester: possible relation with early B cells.
Neoplasms
Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia.
Neoplasms
Interaction analysis between BLK rs13277113 polymorphism and BANK1 rs3733197 polymorphism, MMEL1/TNFRSF14 rs3890745 polymorphism in determining susceptibility to rheumatoid arthritis.
Neoplasms
Involvement of hippocampal agmatine in ?1-42 amyloid induced memory impairment, neuroinflammation and BDNF signaling disruption in mice.
Neoplasms
Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth.
Neoplasms
Localization of 99mTc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses.
Neoplasms
Long-term neprilysin inhibition - implications for ARNIs.
Neoplasms
Lung ultrasound and biomarkers in primary care: Partners for a better management of patients with heart failure?
Neoplasms
Lymphokine-activated killer (LAK) cells discriminate between Epstein-Barr virus (EBV)-positive Burkitt's lymphoma cells.
Neoplasms
Lymphokine-activated killer cytotoxicity in neonatal mononuclear cells: in vitro responses to tumor cell lines from pediatric solid tumors.
Neoplasms
Marker turned target? A case to review neprilysin in ALL (or lessons learned at the American Association for Cancer Research Meetings, 2006).
Neoplasms
Markers of multiple hematopoietic-cell lineages in multiple myeloma.
Neoplasms
Methylation of neutral endopeptidase 24.11 promoter in rat hepatocellular carcinoma.
Neoplasms
Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein.
Neoplasms
Molecular interaction between arsenic hydrate microcrystals and the cell-surface endopeptidase CD10 (neprilysin) - A possible link to the development of renal and cutaneous malignancies upon occupational exposure to arsenic compounds?
Neoplasms
Monocyte markers and the common acute lymphoblastic leukemia antigen on chronic lymphocytic leukemia cells.
Neoplasms
Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2.
Neoplasms
Neutral endopeptidase (NEP) inhibitors - thiorphan, sialorphin, and its derivatives exert anti-proliferative activity towards colorectal cancer cells in vitro.
Neoplasms
Neutral endopeptidase (NEP) is differentially involved in biological activities and cell signaling of colon cancer cell lines derived from various stages of tumor development.
Neoplasms
Neutral endopeptidase depletion decreases colon cancer cell proliferation and TGF-?1 synthesis in indirect co-cultures with normal colon fibroblasts.
Neoplasms
Neutral endopeptidase/CD10 expression in the stroma of epithelial ovarian carcinoma.
Neoplasms
One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [99mTc]Tc-DB4 and [111In]In-SG4 in Mice Treated with Entresto.
Neoplasms
Opioids, Neutral Endopeptidase, its Inhibitors and Cancer: Is There a Relationship among them?
Neoplasms
Overexpression of B7-H4 promotes renal cell carcinoma progression by recruiting tumor-associated neutrophils via upregulation of CXCL8.
Neoplasms
Phenotypic changes in large cell transformation of small cell lymphoid malignancies.
Neoplasms
Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement.
Neoplasms
Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin.
Neoplasms
Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin.
Neoplasms
Radiosynthesis of the 11 C-methyl derivative of LBQ657 for PET investigation of the neprilysin inhibitor sacubitril.
Neoplasms
Rapidly Growing Papillary Well-Differentiated Adenocarcinoma in a Patient With a Helicobacter pylori-Naive Gastric Mucosa.
Neoplasms
Rational redesign of neutral endopeptidase binding to merlin and moesin proteins.
Neoplasms
Rebamipide reduces amyloid-? 1-42 (A?42) production and ameliorates A?43-lowered cell viability in cultured SH-SY5Y human neuroblastoma cells.
Neoplasms
Regulatory role of membrane-bound peptidases in the progression of gynecologic malignancies.
Neoplasms
Requirements for the construction of antibody heterodimers for the direction of lysis of tumors by human T cells.
Neoplasms
Saccharide alterations in rat kidney associated with malignant transformation by injection of dimethylnitrosamine.
Neoplasms
Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression.
Neoplasms
Subpopulations of common acute lymphoblastic leukemia antigen-positive lymphoid cells in normal bone marrow identified by hematopoietic differentiation antigens.
Neoplasms
Synergistic relationship between dipeptidyl peptidase IV and neutral endopeptidase expression and the combined prognostic significance in osteosarcoma patients.
Neoplasms
Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN.
Neoplasms
Telmisartan Protects Against Aluminum-Induced Alzheimer-like Pathological Changes in Rats.
Neoplasms
The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients.
Neoplasms
The common acute lymphoblastic leukemia antigen gene maps to chromosomal region 3 (q21-q27).
Neoplasms
The common acute lymphoid leukemia antigen on b cells of chronic lymphoid leukemia and non-Hodgkin's lymphoma.
Neoplasms
Tumor formation by a human pre-B leukemia cell line in scid mice is enhanced by matrigel and is associated with induction of CD10 expression.
Neoplasms
Tumour suppression through modulation of neprilysin signaling: A comprehensive review.
Neoplasms
VEGF-, KIT protein- and neutral endopeptidase (NEP/CD10)-positive myofibroblasts-precursors of angiogenesis in chorioangiomas?
Neoplasms
[99mTc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models.
Nephrolithiasis
Possible biphasic changes of free radicals in ethylene glycol-induced nephrolithiasis in rats.
neprilysin deficiency
Alzheimer's disease, neuropeptides, neuropeptidase, and amyloid-beta peptide metabolism.
neprilysin deficiency
Amyloid Beta annular protofibrils in cell processes and synapses accumulate with aging and Alzheimer-associated genetic modification.
neprilysin deficiency
Drosophila Neprilysins Are Involved in Middle-Term and Long-Term Memory.
neprilysin deficiency
Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels.
neprilysin deficiency
Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo.
neprilysin deficiency
Loss of neprilysin alters protein expression in the brain of Alzheimer's disease model mice.
neprilysin deficiency
Metabolic regulation of brain Abeta by neprilysin.
neprilysin deficiency
Neprilysin Deficiency Alters the Neuropathological and Behavioral Phenotype in the 5XFAD Mouse Model of Alzheimer's Disease.
neprilysin deficiency
Neprilysin Deficiency Is Associated With Expansion of Islet ?-Cell Mass in High Fat-Fed Mice.
neprilysin deficiency
Neprilysin Deficiency Protects Against Fat-Induced Insulin Secretory Dysfunction by Maintaining Calcium Influx.
neprilysin deficiency
Neprilysin deficiency-dependent impairment of cognitive functions in a mouse model of amyloidosis.
Neuralgia
Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.
Neuralgia
Preventive and alleviative effects of the dual enkephalinase inhibitor (Denki) PL265 in a murine model of neuropathic pain.
Neurobehavioral Manifestations
Psychiatric Manifestations With Sacubitril/Valsartan: A Case Report.
Neuroblastoma
Altered expression of cell surface membrane antigens in a common acute lymphoblastic leukemia-associated antigen-expressing neuroblastoma cell line (SJ-N-CG) with morphological differentiation.
Neuroblastoma
CD10 and CD44 genes of leukemic cells and malignant cell lines show no evidence of transformation-related alterations.
Neuroblastoma
Determination of hypoxic effect on neprilysin activity in human neuroblastoma SH-SY5Y cells using a novel HPLC method.
Neuroblastoma
Effects of hypoxia and oxidative stress on expression of neprilysin in human neuroblastoma cells and rat cortical neurones and astrocytes.
Neuroblastoma
Enhanced neprilysin-mediated degradation of hippocampal A?42 with a somatostatin peptide that enters the brain.
Neuroblastoma
Estrogen stimulates degradation of beta-amyloid peptide by up-regulating neprilysin.
Neuroblastoma
Hydrolysis of atrial and brain natriuretic peptides by the human astrocytoma clone D384 and the neuroblastoma line SH-SY5Y.
Neuroblastoma
Hypoxia-inducible factor-1? mediates up-regulation of neprilysin by histone deacetylase-1 under hypoxia condition in neuroblastoma cells.
Neuroblastoma
Induction of neutral endopeptidase (NEP) activity of SK-N-SH cells by natural compounds from green tea.
Neuroblastoma
Induction of neutral endopeptidase and angiotensin-converting enzyme activity of SK-N-SH cells in vitro by quercetin and resveratrol.
Neuroblastoma
Nobiletin Reduces Intracellular and Extracellular ?-Amyloid in iPS Cell-Derived Alzheimer's Disease Model Neurons.
Neuroblastoma
Recombinant neutral endopeptidase-24.11 expressed in mouse neuroblastoma cells is associated with neurite membranes.
Neuroblastoma
The increased proliferation of cultured neuroblastoma cells treated with vasoactive intestinal peptide is enhanced by simultaneous inhibition of neutral endopeptidase.
Neuroblastoma
The neuroprotector kynurenic acid increases neuronal cell survival through neprilysin induction.
Neuroblastoma
[DNA cytometry analysis in childhood tumors]
Neuroblastoma
[Expression of neprilysin gene is associated with methylation and histone modification on promoter in mouse neuroblastoma Neuro-2a cells].
Neurodegenerative Diseases
Age-associated neurodegeneration and oxidative damage to lipids, proteins and DNA.
Neurodegenerative Diseases
Determination of hypoxic effect on neprilysin activity in human neuroblastoma SH-SY5Y cells using a novel HPLC method.
Neurodegenerative Diseases
Neprilysin protects human neuronal progenitor cells against impaired development caused by amyloid-beta peptide.
Neuroendocrine Tumors
Menin and Daxx Interact to Suppress Neuroendocrine Tumors through Epigenetic Control of the Membrane Metallo-Endopeptidase.
Neurogenic Inflammation
CD10/neutral endopeptidase inhibition augments pulmonary neuroendocrine cell hyperplasia in hamsters treated with diethylnitrosamine and hyperoxia.
Neurogenic Inflammation
Increased pain and neurogenic inflammation in mice deficient of neutral endopeptidase.
Neurogenic Inflammation
Inhibition of neutral endopeptidase (NEP) facilitates neurogenic inflammation.
Neurogenic Inflammation
Inhibition of neutral endopeptidase potentiates neurogenic inflammation in the rat trachea.
Neurogenic Inflammation
Loss of neutral endopeptidase activity contributes to neutrophil activation and cardiac dysfunction during chronic hypomagnesemia: Protection by substance P receptor blockade.
Neurogenic Inflammation
Modulation of neurogenic inflammation by neutral endopeptidase.
Neurogenic Inflammation
Neprilysin levels in plasma and synovial fluid of juvenile idiopathic arthritis patients.
Neurogenic Inflammation
Neurogenic inflammation of the rat trachea: fate of neutrophils that adhere to venules.
Neurogenic Inflammation
Neurogenic inflammation: with additional discussion of central and perceptual integration of nonneurogenic inflammation.
Neurogenic Inflammation
Neurogenic responses in rat lungs after nose-only exposure to diesel exhaust.
Neurogenic Inflammation
Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P.
Neurogenic Inflammation
Neutral endopeptidase and kininase II mediate glucocorticoid inhibition of neurogenic inflammation in the rat trachea.
Neurogenic Inflammation
Neutral endopeptidase and neurogenic inflammation in rats with respiratory infections.
Neurogenic Inflammation
Neutral endopeptidase modulates neurogenic inflammation.
Neurogenic Inflammation
Neutral endopeptidase modulation of neurogenic inflammation in airways.
Neurogenic Inflammation
Regulation of airway neurogenic inflammation by neutral endopeptidase.
Neurogenic Inflammation
Regulation of neurogenic inflammation by neutral endopeptidase.
Neurogenic Inflammation
Substance P is a determinant of lethality in diet-induced hemorrhagic pancreatitis in mice.
Neurogenic Inflammation
The role of substance P in inflammatory disease.
Neurogenic Inflammation
[Neutral endopeptidase (NEP)--modulator of neurogenic inflammation]
Neurogenic Inflammation
[The role of enkephalinase (neutral endopeptidase) in neurogenic inflammation of the respiratory tract]
Neuroinflammatory Diseases
Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure.
Neuroinflammatory Diseases
Interactions between oestrogen and the renin angiotensin system - potential mechanisms for gender differences in Alzheimer's disease.
Neuroinflammatory Diseases
Intranasal Losartan Decreases Perivascular Beta Amyloid, Inflammation, and the Decline of Neurogenesis in Hypertensive Rats.
Neuroinflammatory Diseases
Neuroinflammation drives APOE genotype-dependent differential expression of neprilysin.
Obesity
Cardio- and Neurometabolic Adipobiology: Consequences and Implications for Therapy.
Obesity
ED 05-4 NATRIURETIC PEPTIDES, METABOLIC SYNDROME AND HYPERTENSION: AN INTEGRATED VIEW.
Obesity
Effect of Treatment of Sprague Dawley Rats with AVE7688, Enalapril, or Candoxatril on Diet-Induced Obesity.
Obesity
Emerging Role of Adipocyte Dysfunction in Inducing Heart Failure Among Obese Patients With Prediabetes and Known Diabetes Mellitus.
Obesity
Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels.
Obesity
Improved Insulin Sensitivity with Angiotensin Receptor Neprilysin Inhibition in Individuals with Obesity and Hypertension.
Obesity
Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity.
Obesity
Neprilysin, obesity and the metabolic syndrome.
Obesity
Obesity and aging affects skeletal muscle renin-angiotensin system and myosin heavy chain proportions in pre-diabetic Zucker rats.
Obesity
Obesity-related heart failure with preserved ejection fraction: new treatment strategies.
Obesity
Reduction and fragmentation of elastic fibers in the skin of obese mice is associated with altered mRNA expression levels of fibrillin-1 and neprilysin.
Osteoarthritis
Enkephalinase: a physiologic neuroimmunomodulator detected in the synovial fluid.
Osteoarthritis
Neutral endopeptidase (3.4.24.11) in plasma and synovial fluid of patients with rheumatoid arthritis. A marker of disease activity or a regulator of pain and inflammation?
Osteosarcoma
Synergistic relationship between dipeptidyl peptidase IV and neutral endopeptidase expression and the combined prognostic significance in osteosarcoma patients.
Out-of-Hospital Cardiac Arrest
Serum neprilysin and the risk of death in patients with out-of-hospital cardiac arrest of non-traumatic origin.
Overweight
Low-fat hypocaloric diet reduces neprilysin in overweight and obese human subjects.
Pancreatic Neoplasms
Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues.
Pancreatitis
Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues.
Pancreatitis
The role of neutral endopeptidase in caerulein-induced acute pancreatitis.
Pancreatitis, Chronic
Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues.
Pancreatitis, Chronic
Substance P and neprilysin in chronic pancreatitis.
Paraproteinemias
Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells.
Periodontal Diseases
In vitro study of gingival fibroblasts from normal and inflamed tissue: age-related responsiveness.
Peripheral Nervous System Diseases
Antiallodynic effects of a CCKB antagonist in rats with nerve ligation injury: role of endogenous enkephalins.
Peripheral Nervous System Diseases
Early loss of innervation of cornea epithelium in streptozotocin-induced type 1 diabetic rats: improvement with ilepatril treatment.
Peripheral Nervous System Diseases
Neutral endopeptidase activity is increased in the skin of subjects with diabetic ulcers.
Peripheral Nervous System Diseases
Vascular and Neural Complications in Type 2 Diabetic Rats: Improvement by Sacubitril/Valsartan Greater Than Valsartan Alone.
Phyllodes Tumor
Glial fibrillary acidic protein immunoreactivity in normal and diseased human breast.
Plasmacytoma
B-cell neoplasms of the lymphocytic, lymphoplasmacytoid, and plasma cell types: immunohistologic analysis and clinical correlation.
Pleural Effusion
Renal Cell Carcinoma Presenting as Pleural Effusion.
Pneumonia
Amniotic sac infection syndrome features fetal lung neuroendocrine cell hyperfunction.
Pneumonia, Mycoplasma
Airway hyper-responsiveness to neurokinin A and bradykinin following Mycoplasma pneumoniae infection associated with reduced epithelial neutral endopeptidase.
Polyneuropathies
A Novel Mutation of the Membrane Metallo-Endopeptidase Gene Related to Late-Onset Hereditary Polyneuropathy: Case Report and Review of the Literature.
Polyneuropathies
Charcot-Marie-Tooth disease type 2 caused by homozygous MME gene mutation superimposed by chronic inflammatory demyelinating polyneuropathy.
Polyneuropathies
Long-term neprilysin inhibition - implications for ARNIs.
Polyneuropathies
Rare Variants in MME, Encoding Metalloprotease Neprilysin, Are Linked to Late-Onset Autosomal-Dominant Axonal Polyneuropathies.
Pre-Eclampsia
Increased immunohistochemical expression of neutral metalloendopeptidase (enkephalinase; EC 3.4.24.11) in villi of the human placenta with pre-eclampsia.
Pre-Eclampsia
Serum neprilysin levels are elevated in preeclampsia.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Correlation of karyotype and immunophenotype in childhood acute lymphoblastic leukemia.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Correlation of karyotype and immunophenotype in childhood acute lymphoblastic leukemia; experience at the National Cancer Institute, Cairo University, Egypt.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Differential prognosis detected by immunophenotyping in acute lymphoblastic leukemia of childhood with poor prognostic factors.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Leukemia in infants.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Lineage specific classification of leukaemia: results of the analysis of sixty cases of childhood leukaemia.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Shifts in blast cell phenotype and karyotype at relapse of childhood lymphoblastic leukemia.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
[Immunophenotyping in diagnostic and classification of leukemia]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A human retinoblastoma cell line expressing the common acute lymphoblastic leukemia antigen and displaying an unusual chromosome abnormality.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A monoclonal antibody to common acute lymphoblastic leukemia antigen (CALLA) and its expression on several human tumor cell lines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A monoclonal antibody to common acute lymphoblastic leukemia antigen (neutral endopeptidase) immunostains senile plaques in the brains of patients with Alzheimer's disease.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A newly established human acute lymphoblastic leukemia cell line with characteristics of the earliest B-cell maturation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A novel Japanese Burkitt's lymphoma cell line, P32/Ishida, with a new variant chromosomal translocation (2;14).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A subpopulation of lymph node B-CLL cells expresses the common acute lymphoblastic leukemia antigen.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Ability of human colonic epithelium to express the 4F2 antigen, the common acute lymphoblastic leukemia antigen, and the transferrin receptor. Studies in inflammatory bowel disease and after in vitro exposure to different stimuli.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute leukemia presenting with myeloid and lymphoid cell markers.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute leukemias associated with the 4;11 chromosome translocation have rearranged immunoglobulin heavy chain genes.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute leukemias with both myeloid and lymphoid surface markers. Cytoplasmic alpha-1-anti-chymotrypsin and alpha-1-anti-trypsin as possible indicators of early granulocytic differentiation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Aggressive Diffuse Lymphoma Coexpressing NRAS p21 and C-erbB-2 (neu) Oncogene Products, and CALL A (CD 10).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Altered expression of cell surface membrane antigens in a common acute lymphoblastic leukemia-associated antigen-expressing neuroblastoma cell line (SJ-N-CG) with morphological differentiation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anatomical distribution of call antigen expressing cells in normal lymphatic tissue and in lymphomas.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anti-CALLA antibodies identify unique antigens on lymphoid cells and granulocytes.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Antibody affinity may influence antigenic modulation of the common acute lymphoblastic leukemia antigen in vitro.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Antigenic heterogeneity of clones and subclones from human melanoma cell lines demonstrated by a panel of monoclonal antibodies and flow microfluorometry analysis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Antigenic heterogeneity of human anaplastic gliomas and glioma-derived cell lines defined by monoclonal antibodies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Antigenically defined subgroups of lymphoblastic lymphoma. Relationship to clinical presentation and biologic behavior.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Association of the Neprilysin gene with susceptibility to late-onset Alzheimer's disease.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-cell maturation stages of Burkitt's lymphoma cell lines according to Epstein-Barr virus status and type of chromosome translocation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Biologic and prognostic significance of the presence of more than two mu heavy-chain genes in childhood acute lymphoblastic leukemia of B precursor cell origin.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CALLA negative precursor B lymphoblastic leukemia with MLL gene translocation and an unusual FISH signal pattern.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Calla positive acute lymphoblastic leukemia after etoposide-based therapy for Ewing's sarcoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CALLA-positive myeloma: an aggressive subtype with poor survival.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Can CD10 be used as a diagnostic marker in thyroid pathology?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CD-10 immunostaining differentiates superficial basal cell carcinoma from cutaneous squamous cell carcinoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CD10 immunohistochemical staining in urothelial neoplasms.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CD10 is expressed in cutaneous clear cell lesions of different histogenesis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CD10/NEP is expressed on Thy-1low B220+ murine B-cell progenitors and functions to regulate stromal cell-dependent lymphopoiesis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cellular antigens in nephroblastoma: identification with monoclonal antibodies which recognize hemopoietic cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Changes in membrane enzymes and glycosphingolipids in lymphocytes from HIV-1--infected and noninfected intravenous drug users.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Characterisation of enkephalinase (EC 3.4.24.11) activity on various leukemic cells expressing the common acute lymphocytic leukemia antigen (CALLA).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Characterization of a monoclonal antibody (A12) that defines a human acute lymphoblastic leukemia-associated differentiation antigen.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Characterization of human mammary cell types in primary culture: immunofluorescent and immunocytochemical indicators of cellular heterogeneity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Characterization of malignant and non-neoplastic cell phenotypes in highly malignant non-Hodgkin lymphomas.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Characterization of membrane vesicles circulating in the serum of patients with common acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Characterization of thymocytes expressing the common acute lymphoblastic leukemia antigen.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Circulating CALLA-positive lymphocytes exhibit circadian rhythms in man.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Classification of human leukemia by membrane antigen analysis with xenoantisera.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical and laboratory characteristics of acute leukemia with the 4;11 translocation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical features of common acute lymphoblastic leukemia antigen (CALLA)-positive myeloma: report of four cases.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical significance of HLA-DR+, CD19+, CD10+ immature B-cell phenotype and CD34+ cell detection in bone marrow lymphocytes from children affected with immune thrombocytopenic purpura.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clonal B-cell proliferation in an infant with congenital HIV infection and immune thrombocytopenia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ("enkephalinase"): direct evidence by cDNA transfection analysis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Common acute lymphoblastic leukemia antigen (CD10)-positive Sézary's syndrome.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Common acute lymphoblastic leukemia antigen expressed on leukemia and melanoma cell lines has neutral endopeptidase activity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Common acute lymphoblastic leukemia antigen expression on visceral epithelial cells in several types of glomerulonephritis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Common acute lymphoblastic leukemia antigen: partial characterization by in vivo labeling and isolation of its messenger RNA.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Common acute lymphoblastic leukemia characterized by four different DNA stemlines with heterogeneity in RNA content, antigen expression and sensitivity to chemotherapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Comparative levels of CALLA/neutral endopeptidase on normal granulocytes, leukemic cells, and transfected COS-1 cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Comparison of the expression of terminal deoxynucleotidyl transferase and common acute lymphoblastic leukemia antigen in selected hematologic malignancies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Computer modeling and nanosecond simulation of the enzyme-substrate complex of the common lymphoblastic leukemia antigen (neprilysin) indicates shared residues at the primary specificity pocket (S1') with matrix metalloproteases.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Critical role for Nef in HIV-1-induced podocyte dedifferentiation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Degradation of alpha-melanocyte stimulating hormone (alpha-MSH) by CALLA/endopeptidase 24.11 expressed by human melanoma cells in culture.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Detection of neutral endopeptidase-24.11/CD10 by flow cytometry and photomicroscopy using a new fluorescent inhibitor.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Detection of the common acute lymphoblastic leukemia antigen in the serum of leukemia patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Development of [125I]RB104, a potent inhibitor of neutral endopeptidase 24.11, and its use in detecting nanogram quantities of the enzyme by "inhibitor gel electrophoresis".
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Diagnosis and analysis of the clinical course of T-phenotype acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Discrepancy between flow cytometric analyses of CALLA using two monoclonal antibodies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Distinct reactivity of Burkitt's lymphoma cell lines with eight monoclonal antibodies correlated with the ethnic origin.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Distribution of common acute lymphoblastic leukemia antigen in nonhematopoietic tissues.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Distribution of neutral endopeptidase activity in human blood leukocytes.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Down's syndrome and acute leukemia in children: an analysis of phenotype by use of monoclonal antibodies and electron microscopic platelet peroxidase reaction.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Down-regulation and inactivation of neutral endopeptidase 24.11 (enkephalinase) in human neutrophils.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dual expression of lymphoid/basophil markers on single blast cells transformed from chronic myeloid leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Effect of cocaine and morphine on neutral endopeptidase activity of human peripheral blood mononuclear cells cultured with lectins.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Effects of monoclonal antibodies raised against the common acute lymphoblastic leukemia antigen on endopeptidase-24.11 activity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Elevated common acute lymphoblastic leukemia antigen expression in pediatric immune thrombocytopenic purpura.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Endemic Burkitt's lymphoma: phenotypic analysis of tumor biopsy cells and of derived tumor cell lines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Endopeptidase-24.11 is suppressed in myelin-forming but not in non-myelin-forming Schwann cells during development of the rat sciatic nerve.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linker.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Epithelial-myoepithelial carcinoma of the minor salivary glands: immunohistochemical and morphological features.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Establishment and characterization of a common acute lymphoblastic leukemia cell line with a deletion of chromosome 3 band q26.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Establishment and characterization of a new human Burkitt's lymphoma cell line (WSU-BL).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Establishment of a Ph1-positive human cell line (BV173).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Exon 16 del: a novel form of human neutral endopeptidase (CALLA).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of cALLa/NEP on gliomas: a possible marker of malignancy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of CD10/neutral endopeptidase in normal and malignant tissues of the human stomach and colon.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of common acute lymphoblastic leukemia antigen (CALLA) on human malignant melanoma cell lines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of common acute lymphoblastic leukemia antigen (CD 10) by myelinated fibers of the peripheral nervous system.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of HLA-DR and common acute lymphoblastic leukemia antigens on glioma cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of the common acute lymphoblastic leukemia antigen (CALLA) on the surface of individual cells of human lymphoblastoid lines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of the common acute lymphoblastic leukemia antigen (CD10) in mesenchymal tumors.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression of the T1 (CD5, p67) surface antigen in B-CLL and B-NHL and its correlation with other B-cell differentiation markers.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Failure of B cells in common variable immunodeficiency to transit from proliferation to differentiation is associated with altered B cell surface-molecule display.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Fate of a common acute lymphoblastic leukemia antigen during modulation by monoclonal antibody.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Gastrointestinal Obstruction due to Solitary Lymph Node Recurrence of Alpha-Fetoprotein-Producing Gastric Carcinoma with Enteroblastic Differentiation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Granulocytes and cultured human fibroblasts express common acute lymphoblastic leukemia-associated antigens.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Growth factor control of myoepithelial-cell differentiation in cultures of human mammary gland.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Heparin inhibition of antibody-dependent complement-mediated lysis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Heterogeneous expression of melanoma-associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
High FLT3 expression and IL10 (G1082A) polymorphism in poor overall survival in calla acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Histogenesis of diffuse small cleaved cell lymphoma. An immunohistochemical and molecular genetic (bcl-2 gene) study with comparison to follicular small cleaved cell lymphoma and mantle zone lymphoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Histopathological and immunohistochemical characterization of spontaneously occurring uterine deciduomas in young adult rats.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Human glioma cell lines expressing the common acute lymphoblastic leukemia antigen (cALLa) have neutral endopeptidase activity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Human nasal mucosal neutral endopeptidase (NEP): location, quantitation, and secretion.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Hyperdiploidy of 54 chromosomes with double Ph1 chromosome in lymphoid chronic myelocytic leukemic blast crisis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Identification and characterization of a unique subpopulation (CALLA/CD10/negative) of human neutrophils manifesting a heightened chemotactic response to activated complement.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Identification and cloning of a prethymic precursor T lymphocyte from a population of common acute lymphoblastic leukemia antigen (CALLA)-positive fetal bone marrow cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Identification of myoepithelial cells in human and rat breasts by anti-common acute lymphoblastic leukemia antigen antibody A12.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunocytochemical characterization and identification of SGE1, a rat glomerular epithelial cell line.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunocytochemical identification of cell types in human mammary gland: variations in cellular markers are dependent on glandular topography and differentiation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunocytological and immunochemical analysis on the common acute lymphoblastic leukemia antigen (CALLA): evidence that CALLA on ALL cells and granulocytes are structurally related.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunodiagnosis of childhood ALL with monoclonal antibodies to myeloid and lymphoid associated antigens.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunoelectron microscopy studies on the modulation of common acute lymphoblastic leukemia antigen (CALLA) on NALM-6 cells: delineation of intracellular transport.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunohistochemical Expression of CD10 in Cutaneous Basal and Squamous Cell Carcinomas.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunohistochemical expression of CD10 in cutaneous basal and squamous cell carcinomas.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunohistochemical study of mantle zone lymphoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunologic and clinicopathologic features of common acute lymphoblastic leukemia antigen-positive childhood T-cell leukemia. A Pediatric Oncology Group Study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunophenotype and cytochemical reactions of acute lymphoblastic leukemia in Thai children.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunophenotype of leukemic blasts with small peroxidase-positive granules detected by electron microscopy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunophenotype of lymphoid cells in positive patch tests of allergic contact dermatitis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunophenotypic characterization of follicle-center-cell-derived non-Hodgkin's lymphomas.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Impaired mammary development in tamoxifen-treated prepubertal heifers is associated with altered development and morphology of myoepithelial cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Improved detection of rare CALLA-positive cells in peripheral blood using multiparameter flow cytometry.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
In vitro and in vivo cytotoxic activity of anti-human leukemia monoclonal antibodies SN5c and SN6 daunorubicin conjugates.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
In vitro and in vivo properties of human/mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Increase of neutral endopeptidase-24.11 with cellular density and enzyme modulation with an inhibitor on human Reh6 cell line.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Increased expression of multidrug resistance gene (MDR1) at relapse in a child with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Increased expression of neprilysin (neutral endopeptidase 24.11) in rat and human hepatocellular carcinomas.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Increased serum neutral endopeptidase activity in acute renal allograft rejection.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Induction of B-lymphocyte antigens on the chronic myeloid leukemic cell line K562 using sodium butyrate.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Induction of differentiation of African Burkitt's lymphoma cells by phorbol ester: possible relation with early B cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Induction of HLA-DC/DS (LEU 10) antigen expression by human precursor B cell lines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Induction of plasmacytoid differentiation by phorbol ester in B-cell lymphoma cell lines bearing 8;14 translocations.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inhibition of CD10/neutral endopeptidase 24.11 promotes B-cell reconstitution and maturation in vivo.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interferon-induced changes in expression of antigens defined by monoclonal antibodies on malignant and nonmalignant mononuclear hematopoietic cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Intermediate lymphocytic lymphoma: an immunophenotypic study with comparison to small lymphocytic lymphoma and diffuse small cleaved cell lymphoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Isolation and characterization of adult mammary stem cells from breast cancer-adjacent tissues.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Isolation of pure populations of epithelial and myoepithelial cells from the normal human mammary gland using immunomagnetic separation with Dynabeads.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Isolation of simian virus 40-transformed human mammary epithelial stem cell lines that can differentiate to myoepithelial-like cells in culture and in vivo.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Karyotypic patterns in acute mixed lineage leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukocyte common antigen--a diagnostic discriminant between hematopoietic and nonhematopoietic neoplasms in paraffin sections using monoclonal antibodies: correlation with immunologic studies and ultrastructural localization.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Localization and imaging with radioiodine-labeled monoclonal antibodies in a xenogeneic tumor model for human B-cell lymphoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Long-term follow-up of 14 patients with philadelphia chromosome-positive acute lymphoblastic leukemia following autologous bone marrow transplantation in first complete remission.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Low molecular weight B cell growth factor induces proliferation of human B cell precursor acute lymphoblastic leukemias.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphocyte malignancy and chromosome 14: structural aberrations involving band q11.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoid progenitor cells in severe combined immunodeficiency.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphokine-activated killer (LAK) cells discriminate between Epstein-Barr virus (EBV)-positive Burkitt's lymphoma cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma cell line (FL-18) and Epstein-Barr virus-carrying cell line (FL-18-EB) obtained from a patient with follicular lymphoma: monoclonal derivation and different properties.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Malignant leukemic cell separation by iron colloid immunomagnetic adsorption.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Marked difference in the in vivo antitumor efficacy between two immunotoxins targeted to different epitopes of common acute lymphoblastic leukemia antigen (CD10). Mechanisms involved in the differential activities of immunotoxins.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Markers of multiple hematopoietic-cell lineages in multiple myeloma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Modulation of human acute lymphoblastic leukemia antigen induced by monoclonal antibody in vitro.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Monoclonal antibodies to CALLA do not alter polymorphonuclear functions.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Monoclonal antibody 55 (CD10) and complement used for purging autologous bone marrow in common acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Monoclonal antibody-ricin conjugate cytotoxic to cells expressing the common acute lymphoblastic leukemia antigen (CALLA).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Monocyte markers and the common acute lymphoblastic leukemia antigen on chronic lymphocytic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Murine common acute lymphoblastic leukemia antigen (CD10 neutral endopeptidase 24.11). Molecular characterization, chromosomal localization, and modeling of the active site.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myelomonocytic antigen positive multiple myeloma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myoepithelial cell differentiation markers in prepubertal bovine mammary gland: effect of ovariectomy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neuroblastoma presenting as acute lymphoblastic leukemia but correctly diagnosed after orbital fine-needle aspiration biopsy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neutral endopeptidase 24.11 and angiotensin converting enzyme like activity in CALLA positive and CALLA negative lymphoid cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neutral endopeptidase modulates septic shock.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neutral endopeptidase modulation of septic shock.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neutral metalloendopeptidase associated with the smooth muscle cells of pregnant rat uterus.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Nonhuman primates express human leukemia-associated antigens.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Occurrence of the common acute lymphoblastic leukemia antigen on blast cells of a patient with chronic myelomonocytic leukemia in non-lymphoid blastic phase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Organization of the gene encoding common acute lymphoblastic leukemia antigen (neutral endopeptidase 24.11): multiple miniexons and separate 5' untranslated regions.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
p63 and CD10: Reliable Markers in Discriminating Benign Sclerosing Lesions From Tubular Carcinoma of the Breast?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Persistence of bone marrow lymphocytosis after induction treatment in common acute lymphoblastic leukemia. Marker analysis and significance.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phenotypic changes in large cell transformation of small cell lymphoid malignancies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phorbol ester-induced differentiation of a non-T/non-B human leukemic cell line (REH) to macrophage-like cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Photoradiation methods for purging autologous bone marrow grafts.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Polymorphonuclear neutrophils express the common acute lymphoblastic leukemia antigen.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pre-T chronic lymphocytic leukemia with common acute lymphoblastic leukemia antigen. A new immunologic variant.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Production of human-mouse chimeric antibody by high cell density perfusion culture.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Provocative pattern of rearrangements of the genes for the gamma and beta chains of the T-cell receptor in human leukemias.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Purification of common acute lymphoblastic leukemia antigen positive cells from normal human bone marrow.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Purine metabolism enzyme pattern, cytochemical characteristics and clinicopathologic features of CD10-positive childhood T-cell leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Quantitative analysis of a new marker for common acute lymphoblastic leukemia detected by two-dimensional electrophoresis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Quantitative variation of the common acute lymphoblastic leukemia antigen (gp100) on leukemic marrow blasts.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Rabbit antiserum against a non-T, non-B leukemia cell line that carries the Ph1 chromosome (NALM-1): antibody specific to a non-T, non-B acute lymphoblastic leukemia antigen.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Rapidly Growing Papillary Well-Differentiated Adenocarcinoma in a Patient With a Helicobacter pylori-Naive Gastric Mucosa.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Renal Cell Carcinoma Presenting as Pleural Effusion.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Requirements for the construction of antibody heterodimers for the direction of lysis of tumors by human T cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Ricin A immunotoxins of IgG and Fab of anti-CALLA monoclonal antibody: effect of water soluble long-chain SPDP on conjugate yield, immunoselectivity and cytotoxicity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Role of CD10 Marker in Differentiating Malignant Thyroid Neoplasms from Benign Thyroid Lesions (Immunohistochemical & Histopathological Study).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Secondary T-cell lymphoproliferation after marrow transplantation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Separation of lymphoid and myeloid blasts in the mixed blast crisis of chronic myelogenous leukemia: no evidence for Ig gene rearrangement in CALLA-positive blasts.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Serotherapy of acute lymphoblastic leukemia with monoclonal antibody.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Shedding of the common acute lymphoblastic leukemia antigen (CALLA) by lymphoblastoid cell lines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Significance of common acute lymphoblastic leukemia antigen (cALLA) positive cells in bone marrow of children off therapy in complete remission.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Similarity of TALLA-1, a T-cell acute lymphoblastic leukemia antigen, to GP37.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Somatic cell mutants resistant to ricin, diphtheria toxin, and to immunotoxins.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Stability and cytotoxicity of Fab-ricin A immunotoxins prepared with water soluble long chain heterobifunctional crosslinking agents.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Stages of renal ontogenesis identified by monoclonal antibodies reactive with lymphohemopoietic differentiation antigens.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Structure/function studies of the common acute lymphoblastic leukemia antigen (CALLA/CD10) expressed on human neutrophils.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Subpopulations of common acute lymphoblastic leukemia antigen-positive lymphoid cells in normal bone marrow identified by hematopoietic differentiation antigens.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Superinfection of epithelial hybrid cells (D98/HR-1, NPC-KT, and A2L/AH) with Epstein-Barr virus and the relationship to the C3d receptor.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Suppression of tumor growth by in vivo administration of a recombinant human-mouse chimeric monoclonal antibody.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The common acute lymphoblastic leukemia antigen (CD10)--emancipation from a functional enigma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The common acute lymphoblastic leukemia antigen (neutral endopeptidase-3.4.24.11) gene is located on human chromosome 3.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The common acute lymphoblastic leukemia antigen gene maps to chromosomal region 3 (q21-q27).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The expression of common acute lymphoblastic leukemia antigen by bile canaliculi.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The phenotype of the neoplastic cells of hairy cell leukemia studied with monoclonal antibodies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Thiorphan stimulates clonal growth of GM-CFU in short-term cultures of bone marrow from a healthy donor and from patients with non-Hodgkin lymphoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
TLE1 as an indicator of adverse prognosis in pediatric acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Tonsillar mapping of determinants found on normal lymphoreticular (T,B,K, immature and macrophage) and myeloblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Ultrastructure of myeloma cells in patients with common acute lymphoblastic leukemia antigen (CALLA)-positive myeloma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Undifferentiated leukemia of infancy with t(11:17) chromosomal rearrangement. Coexpressing myeloid and B cell restricted antigens.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Unique epitopes of common acute lymphoblastic leukemia antigen detected by new monoclonal antibodies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Unusual presentation of common acute lymphoblastic leukemia antigen-positive extramedullary disease in childhood. Two patients with isolated masseter muscle involvement.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Use of monoclonal antibodies to identify cerebrospinal fluid lymphoblasts in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[A transient appearance of CALLA positive blastoid cells after allogeneic bone marrow transplantation in a patient with acute lymphoblastic leukemia]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Analysis of newly established monoclonal antibodies against common acute lymphoblastic leukemia antigen]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Characterization of murine monoclonal antibodies against the common acute leukemia antigen (CALLA)]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[DNA cytometry analysis in childhood tumors]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Membrane metalloendopeptidase (CD10/CALLA): distribution, physiologic and pathophysiologic functions and its inhibitors]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Monoclonal antibodies (NU-N1 and NU-N2) reactive with common acute lymphoblastic leukemia antigen]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Monoclonal antibodies against surface antigens of lymphoblasts and blood cells or bone marrow recognize constituents of the human nephron]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Multi-phenotype leukemia in children. Apropos of 18 cases]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Neonatal acute leukemia: apropos of 7 cases]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Neutral endopeptidase activity in human peripheral blood leukocytes]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Preparation and cytotoxicity of McAb-HSA-MTX conjugates]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[The presence of CALLA (common acute lymphoblastic leukemia antigens) and B-cell differentiation antigens in lymphocytic lymphoma]
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Immunologic and clinicopathologic features of common acute lymphoblastic leukemia antigen-positive childhood T-cell leukemia. A Pediatric Oncology Group Study.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Immunological subtypes of acute lymphoblastic leukemia in north India.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Terminal deoxynucleotidyl transferase in acute leukemias by direct immunofluorescence.
Prediabetic State
Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
Prostatic Hyperplasia
Expression, localization and activity of neutral endopeptidase in cultured cells of benign prostatic hyperplasia and prostate cancer.
Prostatic Neoplasms
Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer.
Prostatic Neoplasms
Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase.
Prostatic Neoplasms
CD10 Is Inversely Associated with Nuclear Factor-Kappa B and Predicts Biochemical Recurrence after Radical Prostatectomy.
Prostatic Neoplasms
Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase.
Prostatic Neoplasms
Detection and verification of glycosylation patterns of glycoproteins from clinical specimens using lectin microarrays and lectin-based immunosorbent assays.
Prostatic Neoplasms
Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines.
Prostatic Neoplasms
Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
Prostatic Neoplasms
Expression and immunolocalisation of neutral endopeptidase in prostate cancer.
Prostatic Neoplasms
Expression of neutral endopeptidase, endothelin-1, and nuclear factor kappa B in prostate cancer: interrelations and associations with prostate-specific antigen recurrence after radical prostatectomy.
Prostatic Neoplasms
Expression, localization and activity of neutral endopeptidase in cultured cells of benign prostatic hyperplasia and prostate cancer.
Prostatic Neoplasms
Identification and characterization of two androgen response regions in the human neutral endopeptidase gene.
Prostatic Neoplasms
Induction of neutral endopeptidase activity in PC-3 cells by an aqueous extract of Epilobium angustifolium L. and oenothein B.
Prostatic Neoplasms
Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth.
Prostatic Neoplasms
Linkage and microarray analyses of susceptibility genes in ACI/Seg rats: a model for prostate cancers in the aged.
Prostatic Neoplasms
Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression.
Prostatic Neoplasms
Membrane metalloendopeptidase suppresses prostate carcinogenesis by attenuating effects of gastrin-releasing peptide on stem/progenitor cells.
Prostatic Neoplasms
Methylation of the neutral endopeptidase gene promoter in human prostate cancers.
Prostatic Neoplasms
Multiple androgen response elements cooperate in androgen regulated activity of the type 1 neutral endopeptidase promoter.
Prostatic Neoplasms
Negative regulation of NEP expression by hypoxia.
Prostatic Neoplasms
Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase.
Prostatic Neoplasms
Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression.
Prostatic Neoplasms
Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway.
Prostatic Neoplasms
Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling.
Prostatic Neoplasms
Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis.
Prostatic Neoplasms
Neutral endopeptidase is a myristoylated protein.
Prostatic Neoplasms
Neutral endopeptidase promotes phorbol ester-induced apoptosis in prostate cancer cells by inhibiting neuropeptide-induced protein kinase C delta degradation.
Prostatic Neoplasms
Neutral endopeptidase protein expression and prognosis in localized prostate cancer.
Prostatic Neoplasms
Proliferation of prostate cancer cells and activity of neutral endopeptidase is regulated by bombesin and IL-1beta with IL-1beta acting as a modulator of cellular differentiation.
Prostatic Neoplasms
The impact of amyloid precursor protein signalling and histone deacetylase inhibition on neprilysin expression in human prostate cells.
Prostatic Neoplasms
Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells.
Proteinuria
Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy.
Proteinuria
Inhibition of Both Neutral Endopeptidase and Endothelin-Converting Enzyme by SLV306 Reduces Proteinuria and Urinary Albumin Excretion in Diabetic Rats.
Proteinuria
The Anti-Fibrotic Effect of Mycophenolic Acid-Induced Neutral Endopeptidase.
Pruritus
Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors.
Pulmonary Arterial Hypertension
Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial.
Pulmonary Arterial Hypertension
Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.
Pulmonary Disease, Chronic Obstructive
Chronic obstructive pulmonary disease and sacubitril: explore the role of neprilysin before its inhibition.
Pulmonary Disease, Chronic Obstructive
Decreased Neprilysin and Pulmonary Vascular Remodeling in Chronic Obstructive Pulmonary Disease.
Pulmonary Disease, Chronic Obstructive
Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease. Response to the letter of Siniorakis et al.
Pulmonary Edema
Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2.
Purpura, Thrombocytopenic, Idiopathic
Clinical significance of HLA-DR+, CD19+, CD10+ immature B-cell phenotype and CD34+ cell detection in bone marrow lymphocytes from children affected with immune thrombocytopenic purpura.
Purpura, Thrombocytopenic, Idiopathic
Elevated common acute lymphoblastic leukemia antigen expression in pediatric immune thrombocytopenic purpura.
Renal Insufficiency
Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2.
Renal Insufficiency, Chronic
Chronic kidney disease, heart failure and neprilysin inhibition.
Renal Insufficiency, Chronic
Do plasma neprilysin activity and plasma neprilysin concentration predict cardiac events in chronic kidney disease patients?
Renal Insufficiency, Chronic
LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.
Renal Insufficiency, Chronic
Neprilysin Inhibition and Effects on Kidney Function and Surrogates of Cardiovascular Risk in Chronic Kidney Disease.
Renal Insufficiency, Chronic
Neprilysin inhibition in chronic kidney disease.
Renal Insufficiency, Chronic
Protection of kidney function and tissue integrity by pharmacologic use of natriuretic peptides and neprilysin inhibitors.
Renal Insufficiency, Chronic
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
Renal Insufficiency, Chronic
[Neprilysin inhibition and chronic kidney disease].
Reperfusion Injury
The effect of neprilysin and renin inhibition on the renal dysfunction following ischemia-reperfusion injury in the rat.
Reperfusion Injury
The Rationale of Neprilysin Inhibition in Prevention of Myocardial Ischemia-Reperfusion Injury during ST-Elevation Myocardial Infarction.
Respiratory Distress Syndrome
Expression of neutral endopeptidase activity during clinical and experimental acute lung injury.
Respiratory Distress Syndrome
Neutral endopeptidase in serum samples from patients with adult respiratory distress syndrome. Comparison with angiotensin-converting enzyme.
Respiratory Distress Syndrome
Substance P and neutral endopeptidase in development of acute respiratory distress syndrome following fire smoke inhalation.
Respiratory Hypersensitivity
Airway hyper-responsiveness to neurokinin A and bradykinin following Mycoplasma pneumoniae infection associated with reduced epithelial neutral endopeptidase.
Respiratory Insufficiency
Effect of phosphoramidon - a selective enkephalinase inhibitor - on nociception and behaviour.
Respiratory Tract Infections
Neutral endopeptidase and neurogenic inflammation in rats with respiratory infections.
Retinoblastoma
A human retinoblastoma cell line expressing the common acute lymphoblastic leukemia antigen and displaying an unusual chromosome abnormality.
Retinoblastoma
CD10 and CD44 genes of leukemic cells and malignant cell lines show no evidence of transformation-related alterations.
Rheumatic Diseases
Neprilysin levels in plasma and synovial fluid of juvenile idiopathic arthritis patients.
Rhinitis, Allergic
Role of neutral endopeptidase and kininase II on substance P-induced increase in nasal obstruction in patients with allergic rhinitis.
Rickets, Hypophosphatemic
Two novel variants of the PHEX gene in patients with X?linked dominant hypophosphatemic rickets and prenatal diagnosis for fetuses in these families.
Sarcoma, Ewing
Calla positive acute lymphoblastic leukemia after etoposide-based therapy for Ewing's sarcoma.
Scleroderma, Diffuse
Discrepant expression of neprilysin on fibroblasts in diffuse systemic sclerosis.
Seizures
Enkephalinase inhibition antagonizes the increased susceptibility to seizure induced by REM sleep deprivation.
Seizures
Neuroblastoma presenting as acute lymphoblastic leukemia but correctly diagnosed after orbital fine-needle aspiration biopsy.
Sepsis
Changes in A-type natriuretic peptide and its receptors induced by a neutral endopeptidase inhibitor in a rat model of sepsis.
Shock, Cardiogenic
Impaired plasma B-type natriuretic peptide clearance in human septic shock.
Shock, Septic
Impaired plasma B-type natriuretic peptide clearance in human septic shock.
Shock, Septic
Neutral endopeptidase modulates septic shock.
Shock, Septic
Neutral endopeptidase modulation of septic shock.
Shock, Septic
Relationship between contents of adrenomedullin and distributions of neutral endopeptidase in blood and tissues of rats in septic shock.
Sleep Apnea, Obstructive
Decrease in immunoreactive neutral endopeptidase in uvula epithelium of patients with obstructive sleep apnea.
Sleep Deprivation
Enkephalinase inhibition antagonizes the increased susceptibility to seizure induced by REM sleep deprivation.
Sleep Deprivation
REM sleep deprivation decreases the grooming and shaking behaviour induced by enkephalinase inhibitor or opiate withdrawal.
Spondylarthropathies
Enkephalinase: a physiologic neuroimmunomodulator detected in the synovial fluid.
ST Elevation Myocardial Infarction
Serum neprilysin levels are associated with myocardial stunning after ST-elevation myocardial infarction.
Stomach Neoplasms
Common acute lymphoplastic leukemia antigen (CALLA) and intestinal metaplasia.
Stroke
Novel therapy approach in primary stroke prevention: simultaneous inhibition of endothelin converting enzyme and neutral endopeptidase in spontaneously hypertensive, stroke-prone rats improves survival.
Subarachnoid Hemorrhage
Attenuation of SAH-induced cerebral vasospasm by a selective ECE inhibitor.
Syphilis, Congenital
The etiology of congenital nephrotic syndrome: current status and challenges.
Tetanus
Families of zinc metalloproteases.
Thrombocytopenia
Elevated common acute lymphoblastic leukemia antigen expression in pediatric immune thrombocytopenic purpura.
Thrombosis
The etiology of congenital nephrotic syndrome: current status and challenges.
Toxoplasmosis, Congenital
The etiology of congenital nephrotic syndrome: current status and challenges.
Tuberculosis
Functional characterization of the Mycobacterium tuberculosis zinc metallopeptidase Zmp1 and identification of potential substrates.
Ureteral Obstruction
Renal responses to atrial natriuretic peptide are preserved in bilateral ureteral obstruction and augmented by neutral endopeptidase inhibition.
Urinary Bladder Neoplasms
A new tumor marker for bladder cancer.
Urolithiasis
Circulating adhesion molecules and neutral endopeptidase enzymuria in patients with urolithiasis and hydronephrosis.
Uterine Cervical Neoplasms
CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study.
Ventricular Dysfunction, Left
Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs.
Ventricular Dysfunction, Left
Effects of chronic neutral endopeptidase inhibition on the progression of left ventricular dysfunction and remodeling in dogs with moderate heart failure.
Ventricular Dysfunction, Left
The role of neurohormonal activation in chronic heart failure and postmyocardial infarction.
Virus Diseases
Pathophysiology of airway viral infections.
Virus Diseases
Viral infection increases contractile but not secretory responses to substance P in ferret trachea.
Virus Diseases
[The role of enkephalinase (neutral endopeptidase) in neurogenic inflammation of the respiratory tract]
Wilms Tumor
Cell differentiation in Wilms' tumor (nephroblastoma): an immunohistochemical study.
Wilms Tumor
Critical role for Nef in HIV-1-induced podocyte dedifferentiation.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
3.4.24.11 neprilysin
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
